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2. Abbreviations 
General marks: Species taxonomy names and gene names and are written in cursive. Although 
there are exeptions, Human genes/proteins are generally written in capital letters (PTCH), while mouse 
(Ptch) and Drosophila (Ptc) genes/proteins are written with a capital letter only in the first letter of the 
name. Unless a species is specified or a part of the context, the mouse protein/gene name is used.  
A  Anterior 
AmphiHh Amphioxus Hh protein 
Arrb2  -arrestin 2 
BCC  Basal cell carcinoma 
BMP  Bone morphogen protein 
Boc  Brother of Cdo 
Botv  Brother of Tout velu 
Cdo Cell adhesion molecule-
related/down-regulated by 
oncogenes 
Ci  Cubitus interruptus 
CiA 155 kDa transcriptional 
activator form of Ci 
CiR 75 kDa transcriptional repressor 
form of Ci 
CKI  Casein kinase I 
Cos2   Costal2 
D  Dorsal 
Dhh/DHH Desert hedgehog 
Disp/DISP Dispatched 
Dlp  Dally-like protein 
Dpp  Decapentaplegic 
EXT1/2  Exostosin 1/2 
En  Engrailed 
F  Floorplate 
Fgf10  Fibroblast growth factor 10 
Fu  Fused, a serine/threonine kinase 
Gas1  Growth arrest-specific gene 1 
Gli1-3/GLI1-3 Glioma-associated oncogenes 1-
3 
GliA Transcriptional activator form 
of Gli2/3 
GliR Transcriptional repressor form 
of Gli2/3 
Glis Gli-similar 
Glypican Glycosylphosphatidylinositol 
linked HSPG 
GPCR  G-protein coupled receptor 
GPI   Glycosylphosphatidylinositol 
G-protein Heterotrimeric GTP-binding 
regulatory proteins 
GRK2 G-protein coupled receptor 
kinase 2 
GSK3  Glycogen synthase kinase 3 
Hedge N-terminal Hh fragment 
(signaling component) 
Hh  Hedgehog 
Hh-N N-terminal Hh fragment 
(signaling component) 
Hh-Np Dual lipid modified Hh-N 
fragment (p for processed) 
HPLC High performance (pressure) 
liquid chromatography 
HIP  Hedgehog interacting protein 
Hog C-terminal (autocatalytic) 
domain of Hh 
HSC  Hedgehog signaling complex 
HSPG  Heparin sulfate proteglycan 
Ihh  Indian hedgehog 
Ihog  Interference hedgehog 
IP  Intra peritoneal 
LC  Liquid chromatography 
Lpp  Lipophorin 
LRP2 Low density lipoprotein-related 
protein 2  
LRX  Liver X receptor 
MEF  Mouse embryonic fibroblast 
MN  Motor neurons 
MP  Micro particles 
MS  Mass spectrometry 
N  Notochord 
NMR Nuclear magnetic resonance 
spectroscopy 
NPC1 Niemann–Pick type C1 disease 
gene/protein 
NO  Nitric oxide 
OHC  hydroxycholesterol/oxysterol 
OSBP  Oxysterol binding protein 

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ORP  OSBP related protein 
P  Posterior 
PI4P Phosphatidylinositol-4 
phosphate  
PKA  Protein kinase A 
PKC  Protein kinase C 
Ptc/PTCH  Patched 
Ptc-1-3  Patched gene homologs 1-3 
Ptr  Patched related gene/protein 
RND  Resistance nodulation division 
SANT  Smo antagonist 
SIM  Selected ion monitoring 
Shh/SHH Sonic hedgehog 
Ski/Skn/SKI Skinny hedgehog 
Smo  Smoothened 
Sotv  Sister of Tout velu 
SSD  Sterol sensing domain 
STT4 kinase Staurosporine and temperature 
sensitive PI4P kinase 
SuFu   Supressor of Fused 
TGF  Transforming growth factor  
TLC  Thin layer chromatography 
TIC  Total ion current 
Ttv  Tout velu 
V  Ventral 
V0-V3  Interneurons 
Wg/Wnt Wingless 
ZPA  Zone of polarizing activity  
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4. Introduction 

Inter- and intracellular signaling is a key biological feature of all organisms, from 
single cell organisms like bacteria to multi-cellular organisms like vertebrates. Cellular 
signaling occurs in several ways; by direct contact between cells (juxtacrine signaling), 
by secreted ligands that act on the ligand producing cell itself (autocrine signaling), by 
secreted ligands that act on neighboring cells over short distances (paracrine signaling) 
and by secreted ligands that act over large distances (endocrine signaling). The ligands 
can be peptides, lipids and other molecules, and each ligand can activate a specific 
response by targeting a certain receptor (or receptors) on the surface or inside the 
receiving cell. Signal pathway activation is often followed by a signaling cascade where 
the signal is amplified by the use of kinases, phosphatases and secondary messengers. 
The activation of a signaling cascade can have multiple outcomes, including alterations in 
the intracellular concentration of specific ions, such as Ca2+, changes in enzymatic 
activity, and regulation of transcription factor activity. These changes alone or in 
combination control cell function and behavior. Cellular signaling plays a vital role in 
biological processes like development, tissue homeostasis, tissue repair, cell growth and 
immunity. Changes or errors in cell signaling are linked to various human diseases and 
disorders, and the identification of molecules that can activate (agonize) or inhibit 
(antagonize) signaling pathways is an important field of medical research and drug 
discovery.  
 
4.1 History of the Hedgehog pathway 

The Hedgehog (Hh) pathway is a highly conserved signaling pathway that plays a 
vital role in embryonic development, as well as being involved in several human 
disorders and diseases. The first member of the Hedgehog pathway was identified in 
1980 [2] by Christiane Nüsslein-Volhard and Eric Wieschaus who performed a series of 
genetic screens on the fruit fly Drosophila melanogaster in the late 1970s and early 
1980s. The fruit flies have several strengths as a genetic model organism. The small flies 
are easy to maintain in large numbers due to their small size, simple needs and quick 
generation time. The genetic screens were based on chemically induced 
random mutations that were linked to various phenotypes in the easily observable 
developmental stages of the fruit fly, especially the larval body segmentation. Based on 
this technique, the two researchers identified more than 50 genes that were involved in 
embryonic development, and thus laid the basis for much of our current understanding of 
development in the fruit fly as well as vertebrates. Their work was recognized in 1995 



when they earned the Nobel Prize in Physiology or Medicine together with the 
developmental geneticist Edward B. Lewis. One of the mutations they induced resulted in 
a distinct phenotype of short larva where the ventral cuticular denticles formed a dense 
lawn instead of the distinct segmented bands in the wild type (Figure 1).  
 
 
 
Due to the close resemblance between this stubby and “hairy” phenotype and a 
hedgehog, the gene harboring the loss-of-function mutation was named Hedgehog (Hh). 
Early research suggested that the Hh gene encoded a protein involved in cell-cell 
signaling [28,29], and this was later confirmed when the Drosophila Hh gene was cloned 
[30–33]. It was quickly apparent that the Hh gene was highly conserved in vertebrates, as 
homologues was identified in Mus musculus (mouse) [34], Danio rerio (zebrafish) [35], 
Gallus gallus (chicken) [36], Xenopus laevis (frog) [37], Rattus rattus (rat) [38], Homo 
sapiens (human) [39,40] and many other species. In total three distinct Hh homologues 
were identified in vertebrates, contrasting the one Hh gene found in Drosophila. While 
two of the vertebrate homologues were named after hedgehog species, Indian Hedgehog 
(Ihh) and Desert hedgehog (Dhh), the third member was named Sonic Hedgehog (Shh) 
after the Sega videogame character Sonic the Hedgehog [34]. The gene Patched (Ptc) was 
identified alongside hedgehog in the Drosophila segmentation studies [2]. Ptc was later 
identified as a target of Hh in Drosophila segmentation, and Ingham et al. suggested early 
that Ptc could be the Hh receptor [29]. Still the focus shifted for a while to another gene 
implied in Hh signaling, called Smoothened (Smo), that was proposed as the Hh receptor 
[41,42]. Further studies, however, revealed that Ptc was indeed the receptor for the Hh 
protein ligands [43–46]. The transcription factor Cubitus interruptus (Ci) was identified 
 
 
Figure 1. Ventral cuticular pattern of fixed Drosophila larva shortly after hatching, showing normal wild type 
larva, and a larva homozygous for hedgehog. In the Hedgehog mutant the segmentation is lost, with the resulting 
cuticle lawn phenotype appearing (modified from (Nüsslein-Volhard and Wieschaus 1980) [2]). 


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as the key response element in Hh signaling [47,48], and later three mammalian Ci-
related proteins with similar functions, named Glioma-associated oncogens 1-3 (Gli1-3), 
were found [49,50].  
 
4.2 The Hedgehog pathway in development 

Cellular signaling is a key aspect in the developmental systems that drive the 
development of a fertilized egg (a zygote) into an adult organism. Important 
developmental systems are differentiation, growth, pattern formation, segmentation and 
morphogenesis. The zygote is totipotent, which entails that it has the potency to develop 
into every kind of cell that the adult organism contains, as well as extraembryonic tissues 
such as the placenta. Each cell type maintains a particular pattern of gene expression, and 
the development of a specific cell type is called differentiation. Gene expression is 
regulated by transcription factors and signaling proteins and a certain pattern of gene 
expression in a differentiated cell can be maintained or altered depending on the signals 
the cell receives. Embryogenesis in placental mammals start with the cleavage of the 
zygote into eight totipotent cells, and these cells form a spherical shape called a morula. 
The outer cells of the morula then develop into trophoblast cells that give rise to the 
extraembryonic tissues, while the cells inside the morula develop into the inner cell mass. 
The inner cell mass contains pluripotent cells that can give rise to the three germ layers, 
the endoderm, mesoderm and ectoderm. These cells are no longer defined as totipotent as 
they cannot form extraembryonic tissues. The growth of the embryo is achieved by 
increasing the number of cells through repeated cellular divisions, called cell 
proliferation, and as the embryo grows the cells differentiate into specific cell lineages 
and further into specific cell types. While the cells of the inner cell mass are pluripotent, 
they lose a part of their potency as they develop into specific cell lineages. In the adult 
body, cells are classified as adult stem cells, multipotent progenitor cells, unipotent 
precursor cells and differentiated cells. Multipotent cells have the potential to give rise to 
a limited number of cellular lineages, while unipotent cells only have the capacity to 
develop into one cell type.  
 
Pattern formation is the process by which equivalent cells develop more complex 
structures and organizations of cell fate, and is for instance important in determining 
which cells develop into which organs. Pattern formation is controlled by genes, and is 
best understood in the anterior-posterior axis formation in Drosophila larva. Pattern 
formation involves signaling between adjacent cells and gradients of secreted signaling 
ligands, called morphogens. Segmentation is the division of a body plan into a series of 



repetitive segments, an example being the human spinal cord, while morphogenesis refers 
to the process by which a part of a developing system forms a defined shape.  
 

 
The first insights into the role of the Hh protein in development were its 
involvement in the segmentation of the fruit fly larva [2], and in the development of adult 
fly appendages [51–55]. Hh and another signal that was also identified in early 
Drosophila studies, Wingless (Wg) [56], establishes the parasegmental boundary between 
the separate segments in the fruit fly larva epidermis. While Wg is expressed by a narrow 
band of cells on the posterior (P) side of the segment, Hh is expressed by a narrow band 
of cells on the anterior (A) side, and the Wg and Hh expressing cells lie in juxtaposition 
on each side of the parasegmental boundary. Hh expression is maintained by Wg induced 
expression of Engrailed (En) and Wg expression is in turn regulated by Hh. The two 
ligands mutually thus exclude eachothers expression; maintaing a tight boundary.  
 
 
Figure 2. Hh signaling in mouse development and tissue patterning, including a cartoon of Ptch 
expression during mouse embryonic development, as well as bars depicting the approximate embryonic 
stages when Shh, Ihh and Dhh are involved in development and patterning (modified from Varjosalo 
and Taipale, 2008 [3]). For refrences see [3].  

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An important feature of Hh signaling is that the ligands are able to both act on 
short distance, and act over a long range, controlling cell fates as a function of Hh 
concentration. In Drosophila, Hh is required for the development of the wings and legs as 
well as the patterning of the embryonic segments [57]. One such role is the formation of 
posterior/anterior axis and dorsal/ventral axis in the early embryo. In the development of 
the wing imaginal disc, the posterior cells express and secrete Hh proteins that act on 
cells in the neighboring anterior compartment to induce the expression of target genes 
including Decapentaplegic (Dpp). Dpp encodes a member of the transcription growth 
factor  (TGF)/bone morphogen protein (BMP) family [51,54] that diffuses bi-
directionally into both the A and P compartments, functioning as a long range morphogen 
that controls the growth and patterning of the cells throughout the wing [58,59] (Figure 
3A). While Hh exerts an effect in the whole imaginal disk through its induction of Dpp 
expression, it also acts as a short rage signal that regulates the expression of Ptc and 
Engrailed (En) within spatially limited regions [15].  
 
Mammalian Hh homologues have critical roles in developmental stages as well as 
having important functions in the adult body. Shh has emerged as the most important of 
the three homologues, and is the one that has been most extensively studied. During 
mammalian development, Shh is involved in the patterning of several parts of the 
embryo, including the neural tube and midline structures in the brain, the limbs, the teeth, 
internal organs, the gut, and bone growth. The role of the Hh signaling in development 
has been reviewed in detail by Tabin et al. [60]. Figure 2 depicts the role of Shh, Ihh and 
Dhh in mouse tissue patterning and development, as reviewed by Varjosalo and Taipale 
[3]. In the patterning of the neural tube, cells in the notochord (N) and floor plate (FP) 
express Shh (Figure 3B). The Shh gradient that results from this expression is involved in 
the “programming” of different cell fates in the ventricular zone of the ventral neural tube 
[21,61–63]. Factors that influence the cellular response to a Hh signal include the 
threshold and the signal strength and durance. The spinal chord patterning by Shh 
involves the formation of several distinct neuronal subtypes (Figure 3B); the motor 
neurons (MN) and the interneurons (V0-V3). These subpopulations are defined by the 
strength and durance of the Shh signal. A similar mechanism is involved in the patterning 
of the digits in the developing limb, where a Shh gradient is involved in the patterning of 
the anterior-posterior axis. Shh is expressed in the posterior compartment of the limb bud 
that is called the Zone of Polarizing Activity (ZPA) (Figure 3C).  
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Figure 3. Hh signaling in development: A. Hh protein (blue) is produced by cells in the posterior (P) 
compartment of Drosophila wing imaginal disk, and diffuses towards the anterior (A) compartment where it 
induces neighboring A compartment cells to produce Dpp. Dpp (dark pink) then diffuses into both A and P 
compartments, controlling cell growth and patterning in the whole wing. Hh also acts as a local morphogen to 
specify patterning by regulating target gene expression, such as Ptc and En, within different spatial limits). 
(modified from Jia and Jiang, 2006 [7] and Strigini and Cohen, 1997 [15]). B. Shh protein produced by the 
notochord (N) and the floor plate (FP) in the ventral (V) part of the neural tube forms a gradient towards the 
dorsal side (D) that mediates the patterning of the neural tube, and the formation of motor neurons (MN) and 
interneurons (V0-V3) (modified from Jacob and Briscoe, 2003 [21]). C. In the patterning of the mouse limb 
Shh protein (blue) forms a gradient from the P compartment towards the A compartment, directing the 
patterning of the presumptive region of digits (P1-5) and the resulting digit morphological identities (D1-5) 
through the different developmental stages (modified from Tamura et al. 2011 [25]). D. Lung branching is 
mediated by the combined effect of Fgf10 and Shh signaling between the mesenchyme and epithelium. 
Mesenchymal cells secrete Fgf10 (red) that induce proliferation and growth of epithelial cells. Fgf10 also 
induces expression of Shh (blue) in the epithelial cells (left), which in turn inhibits Fgf10 expression in 
neighboring mesenchymal cells (middle). The continued Fgf10 expression further away on each side of the 
bud continues to induce growth, leading to a branching of the growth towards the two sides (right) (modified 
from Robb W. Glenny, 2011 [27]). 
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Interestingly researchers have found that if they take out a part of the tissue from the ZPA 
and transplant it from the posterior side to the anterior side of the limb bud, the digit 
development is patterned from both sides of the limb bud, resulting in a mirror image 
duplication of the digits [64,65]. These examples of anterior/posterior and dorsal/ventral 
axis formation all build on the same principle, namely the generation of a signaling 
gradient by Hh ligands that act as a morphogen. Shh is also required for the correct 
formation of the lungs [66–68] where it is involved in lung branching morphogenesis 
[27,69]. Lung branching is mediated through interaction between the epithelium and the 
distal mesenchyme. The mesenchyme secretes Fibroblast growth factor-10 (Fgf10), 
which in turn activates epithelial proliferation and growth, as well as expression and 
secretion of Shh. As the budding epithelium grows towards the mesenchyme, secreted 
Shh inhibits expression of Fgf10 in the neighboring mesenchyme. Further away in the 
mesenchyme the Fgf10 expression is retained, resulting in a branched growth of the 
epithelial bud towards the Fgf10 expressing regions on each side (Figure 3D). 
 
While playing a vital role in vertebrate development, Shh signaling is also 
important in the adult body. There are reports of the involvement of Shh in the 
maintenance of stem cells in various tissues [70], including neural [70–76], mammary 
[77], gastric [78], and hematopoietic stem cells [79,80], but as the term stem cells in some 
cases is more loosely defined, this may be more progenitor like cell populations. Shh has 
also been reported to be critical for regeneration of the pulmonary epithelium [81], 
prostate epithelium [82] and the exocrine pancreas [83]. Many of these tissues are the site 
for development of cancers that harbor Hh signaling, as will be detailed below. Shh is 
required for the proper formation of the hair follicle bulb and hair production during the 
postnatal hair cycle [84]. Hh signaling may have a role in regulating insulin in the murine 
pancreas [85], and Shh has been identified as an important factor in wound healing [86–
89], possibly by promoting angiogenesis in the wounded tissue [87].  
 
4.3 The Hedgehog signaling pathway 

In brief, the key signaling components in the hedgehog pathway are the ligands, 
Hh and Shh, the cell membrane receptors, Ptc and Smo, lipophilic signal mediators and 
the signaling complex containing the transcription factors Ci/Gli1-3. In absence of Hh, 
Ptc acts by suppressing the function of Smo by regulating the distribution of cholesterol 
and oxysterols in the cells and by regulating the synthesis of the phospholipid 
phosphatidylinositol-4-phosphate (PI4P). In the lack of active Smo, the Ci/Gli signaling 
complex releases the repressor form of the Ci/Gli proteins. The repressor form of the 
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transcription factors is then translocated to the nucleus where it blocks the transcription 
of target genes. When Hh is present, it binds and blocks the function of Ptc, thus 
releasing Smo from Ptc mediated suppression. Activation of Smo then leads to a change 
in the activity of the Ci/Gli signaling complex, resulting in the release of activating Ci/Gli 
proteins. The activating form of the transcription factors then translocate to the nucleus to 
activate the transcription of target genes. While active Ptc and Smo are located in the cell 
membrane in Drosophila, they are localized in the primary cilium in vertebrates. The Hh 
pathway’s double-negative regulation, with the Hh ligand inhibiting Ptc and preventing it 
from inhibiting Smo, resulting in gene expression, is quite different from the “normal” 
scheme of cellular signaling in which a ligand activates a receptor and a signal cascade. 
The important role played by cholesterol, oxysterols and PI4P in mediating the Hh signal 
is also a unique feature of this pathway. The signaling mechanisms and protein 
interactions involved in the Hh signaling pathway are further detailed below.  

4.3.1 Maturation and movement of hedgehog ligands 
 
As briefly described above, the Hh proteins act as cell-cell signaling molecules. 
The Drosophila Hh and its mammalian counterparts are all synthesized as a pre-protein 
that enters the secretory pathway. This pre-protein contains three parts, a signal sequence, 
a C-terminal domain that has an autocatalytic activity, and an N-terminal domain that 
contains the signaling properties. After a removal of the signal sequence, the Hh 
precursor is further matured as the C-terminal domain catalyzes the cleavage of the 
unfinished precursor into two fragments [90–92], the N-terminal Hh fragment (Hh-N) 
(also named “hedge”) and the C-terminal fragment (named “hog”). The C-terminal 
domain also catalyzes the addition of a cholesterol moiety to the C-terminal part of Hh-N 
[93,94]. The Hh-N fragment is further modified by the addition of a palmitate to a 
cysteine residue near the N-terminal end of Hh-N by an acyltransferase called Skinny 
Hedgehog (Ski) (murine Skn, human SKI or HHAT) [95–97], forming a dual lipid 
modified Hh ligand (Hh-Np) (p for processed). Hh-Np is then transported to the cell 
membrane where the hydrophobic property of the cholesterol and palmitate moieties 
tethers it to the phospholipid bilayer. While membrane tethered Hh-Np can act on 
neighboring cells, the Hh gradients displayed in the developmental stages still require a 
soluble form of Hh. It seems illogical that a lipid-modified protein should be able to 
diffuse over a long range, as lipid modifications normally anchor proteins to the 
membrane. Paradoxically, although the non-lipid modified Hh-N diffuses much further 
than Hh-Np, it can only activate low level targets, probably due to a low affinity for the 
plasma membrane and for proteins that are implicated in Hh movement [98]. Hh-Np has 
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been shown to form multimeric complexes where the hydrophobic moieties cluster at the 
core of the complex, and these multimeric complexes are capable of long range signaling 
[95,99,100]. Active multimeric Hh complexes can isolated from tissue-culture-cell 
supernatants, and vary in size between 158 and 4.000 kDa, equivalent to 6-160 times the 
monomer size [101]. The release of Hh-Np is dependent on the activity of a Ptc related 
protein called Dispatched (Disp) [102–105]. Hh-Np co-localizes with the Apo-lipoprotein 
Lipophorin (Lpp) in lipoprotein particles in Drosophila, and lipoproteins may be required 
for Hh signaling in the fly [106,107]. It has also been demonstrated that Shh can be 
carried by micro particles (MP), small fragments of cell membrane that is shed from the 
plasma membrane of activated/apoptotic T-cells [108]. Similarly small membrane 
fragments, called nodal vesicular parcels have been implied in left right patterning in 
mouse development [109]. MP’s containing Shh may also contribute to reparative 
neovascularization after ischemic injury, by regulating the nitric oxide (NO) pathway and 
genes involved in angiogenesis [110]. In Drosophila the movement of modified Hh 
protein across several cells requires the expression of glycosaminoglycan transferases 
like Tout velu (Ttv), Sister of Tout velu (Sotv) and Brother of Tout velu (Botv), enzymes 
that are involved in the synthesis of heparin sulphate proteglycans (HSPG), implicating 
that HSPG’s are required for the movement of Hh ligands [111,112]. The exotosin (EXT1 
and EXT2) proteins are homologues of Ttv and Sotv that have similar functions in 
mammals [113,114]. The glycosylphosphatidylinositol (GPI) linked HSPG (Glypicans) 
Dally and Dally-like protein (Dlp) are substrates of Ttv that facilitate movement of Hh 
ligands along cell membranes [115–117] by binding of Hh to the heparin sulfate moieties. 
Dally and Dlp also recruit Lpp to the membrane of the Hh secreting cells, mediating the 
interaction between Lpp and the Hh ligand [106]. It has been suggested that the 
mechanism of Hh release is that complexes of Hh, Lpp and glypicans are released from 
the cells by cleavage of the GPI anchor of Dally/Dlp [118]. In addition, metalloproteases 
may be involved in the release of Hh from cells [119]. Other membrane-anchored 
proteins that influence Hh transport and gradients have been described, and Hh gradient 
formation has been reviewed in detail by Torroya et al [120]. 
 
Several proteins have been identified that affect the reception of the Hh ligand in 
the receiving cells, including the transmembrane proteins Interference hedgehog (Ihog) 
and Brother of Ihog (Boi) in Drosophila, and the vertebrate homologs “Cell adhesion 
molecule-related/down-regulated by oncogenes” (Cdo) and Brother of Cdo (Boc). These 
proteins facilitate binding of Hh ligands to the Ptc receptor in a synergistic manner 
[121,122], and their expression is down regulated in response to Hh signaling in 
mammals. The membrane protein Growth Arrest-Specific Gene 1 (Gas1) has an activity 
similar to Cdo/Boc, promoting Hh binding to Ptc [123,124]. Similar to Ihog/Boi and 
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Cdo/Boc, Gas1 is down regulated in response to Hh, serving as a negative feedback to Hh 
signaling. 
 
 
 
 
 
Figure 4. Maturation, release, movement and signal reception of the Hh ligands. The maturation of the Hh 
protein involves signal sequence cleavage, autocatalytic cleavage and addition of cholesterol and subsequently, 
addition of palmitic acid. Mature Hh proteins associate with the cell membrane and are packaged into multimeric 
units (and lipoproteins) by Dispatched, facilitating their release. Movement of Hh across cells requires HSPG 
and Glypicans, and the synthesis of the heparin sulfate side chains on HSPG and Glypicans require the activity 
of Ttv, Botv, Sotv/EXT1-3. Megalin, Ihog/Boi/BOC/CDO and Gas1 positively influence Hh recruitment and 
binding to Ptc, while HIP and Ptc sequesters Hh ligands. Upon binding Ptc, the Hh signal pathway is activated. 
Parts of the figure are modified from Varjosalo and Taipale, 2008 [3], Jiang and Hui, 2008 [12], Wilson and 
Chuang , 2010 [9]. 
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Megalin, also known as Low density lipoprotein-related protein 2 (LRP2) is a 
multi-ligand binding receptor in the plasma membrane of endothelial cells, that binds 
lipoproteins [125,126] and is involved in the uptake of a range of different molecules and 
proteins into cells [127]. Megalin is involved in the recovery of vitamin D in the renal 
tubule [128], and has been shown to bind the Hh protein as a positive regulator of the 
pathway [129]. Mice that lack Megalin experience defects in forebrain development, with 
a holoprosencephalic phenotype similar to Shh knockout mice [130]. Hh proteins that 
bind to Ptc is internalized and degraded, and thus the Ptc protein does not only mediate 
the signal reception, but also acts to sequester Hh ligands [131]. As Hh induces Ptc 
expression, Ptc acts in a negative feedback loop from Hh pathway activation to limit the 
range of diffusing Hh. Similarly, a protein called hedgehog-interacting protein (HIP) also 
binds and sequesters Hh ligands, limiting the range and strength of Hh signals. HIP is 
expressed both as a cell membrane bound and as a soluble extracellular protein [131–
133]. For clarity Hh-Np will be referred to as Hh hereafter. The maturation, secretion, 
movement and reception of Hh ligands are detailed in Figure 4. 
 
4.3.2 Hh signal reception; Patched, Smoothened, lipids and cilia. 

There are two vertebrate homologues of Ptc, Ptch1 and Ptch2, and while Ptch1 
function seems to be equivalent to Ptc, the function of Ptch2 function is not well known. 
Still there are indications that Ptch2 may have overlapping functions to Ptch1 in certain 
tissues [134–136]. Ptch is a 12-pass multimeric transmembrane domain protein 
[29,43,44,46,57,137–140], that have a sterol-sensing domain (SSD), and that share 
sequence similarity to resistance nodulation division (RND) family of proton-driven 
transmembrane transporter proteins, often called RND permeases [141]. Proteins carrying 
SSD domains are generally involved in sterol metabolism or vesicle transport [142], 
while RND permeases are membrane pumps that have rather broad substrate specificities. 
It seems that, similar to RND permeases, Ptch forms trimers in the cell membrane [143]. 
In addition to the protein Disp that is needed for Shh release, the closest relative of Ptch 
is a protein encoded by the Niemann–Pick type C1 disease gene (NPC1). NPC1 was 
discovered through its association with Niemann–Pick syndrome, a disease in cholesterol 
storage/metabolism [144,145]. Smo is a 7-pass transmembrane domain protein that is 
similar in structure to a family of 7-transmembrane heterotrimeric GTP-binding 
regulatory proteins (G-protein)-coupled receptors (GPCR). Although some reports 
suggest that Smo could function like other GPCR’s by activating Gi-family members 
[146–151] this still remains to be proven [152]. 
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While it was first believed that Ptch blocks Smo by direct binding, this model was 
later discarded in favor of a catalytic model, as it was discovered that Ptch can inhibit 
Smo at a stoichiometry of 1:50 [153]. Several lines of evidence now point towards Ptch 
being a sterol pump, and towards Smo being a sterol receptor [153]. Interestingly the data 
does not point towards one specific ligand, and the activity of Smo can be modulated by a 
range of molecules, from endogenous metabolites such as cholesterol [154], oxysterols 
[155,156] and provitamin D3 and/or vitamin D3 [157] as well as a number of synthetic 
small molecules that antagonize and agonize Smo activity [14,158]. Ptch has also been 
implied in the transport of some of these molecules. For instance, there is some evidence 
that Ptch acts as a pump that increases cholesterol efflux from the cell [154]. In support of 
this model, the binding of Shh to Ptch led to an increase in the intracellular levels of 
cholesterol. The addition of cholesterol also induced Hh pathway activity similarly to Shh 
and the Hh agonist purmorphamine [154]. Oxysterols, or hydroxycholesterols (OHC), are 
a group of oxygenated 27-carbon cholesterol derivatives that emerge from direct sterol 
oxidation or from metabolic pathways involved in the formation of sterols, steroids and 
bile acids. Several oxysterols have been implied in Hh signaling as factors that lead to 
ciliary translocation and activation of Smo [155,156], and recent data indicate that 
oxysterols can act as allosteric modulators of Smo [159]. An identified connection 
between mutations in enzymes involved in cholesterol synthesis and phenotypes 
associated with mutations in the Hh pathway was first interpreted as evidence that 
cholesterol modification of the Hh protein was essential. However, cholesterol synthesis 
was later shown to be essential for correct transmission of the Hh signal in the receiving 
cell at the level of Smo [160], supporting the idea that cholesterol and oxysterols are 
activators of Smo. Mutation based analysis of the Ptch protein has also shown that a 
functional SSD domain is essential for Smo repression [161]. It has also been reported 
that another sterol related molecule, pro-vitamin D3 (7-dehydrocholesterol), can be 
pumped out of cultured cells by Ptch, and that provitamin D3 and its metabolite, vitamin 
D3, are potent antagonists of Smo [157]. In addition it has been proposed that Ptc 
regulates Smo in Drosophila by recruiting lipoproteins and a lipoprotein derived 
lipophilic Smo antagonist to the endosomes that Smo is trafficking through [162]. Ptch 
has also been implied in the regulation of the intracellular levels of the phospholipid 
phosphatidylinositol-4 phosphate (PI4P), possibly through inhibition of the STT4 kinase 
(staurosporine and temperature sensitive PI4P kinase) [163], the kinase that forms PI4P. 
Smo activation was also shown to require PI4P [163]. 
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While implied in Hh signaling, oxysterols are also involved several biological 
mechanisms, including cholesterol homeostasis [164], apoptosis [165–167], 
atherosclerotic plaque formation [168], cell differentiation [169] and signaling [170]. 
Several oxysterols occur naturally, including 25-OHC (cholest-5-ene-3, 25-diol), 24S-
OHC (cholest-5-ene-3, 24-diol), and 27-OHC (cholest-5-ene-3, 27-diol) [171]. 
Oxysterols have been described to excerpt their effect in the cells by acting as ligands for 
the nuclear receptors of the liver X receptor (LXR) family [172–174]. However 
oxysterols appear to have many other effects in cells in addition, and an oxysterol binding 
protein (OSBP) [175,176] and several OSBP related proteins (ORP’s) have been 
identified. The OSBP/ORP family has been characterized both in mouse [177] and human 
[178], and the human family consists of 12 OSBP/ORP family members, encoding at 
least 16 different transcripts, many of which appear in short and long splice variants 
[179]. The OSBP family is involved in the control of lipid metabolism, sterol transport, 
signal transduction, and vesicular transport [170,180–187] but have not yet been linked to 
the Hh pathway. The oxysterols found to activate Hh signaling are 20-OHC, 22S-OHC, 
24S-OHC and 25-OHC [155,156], and while 24S-OHC is synthesized by cholesterol-24-
 
Figure 5. Structure of cholesterol and Hh pathway activating hydroxycholesterol (OHC) products, 
24S-OHC, 25-OHC, 22S-OHC and 20-OHC. The enzymes or pathways involved in synthesis of the 
oxysterols are also indicated. The figure is modified from Olkkonen et al, 2012 [1]. 
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hydroxylase (encoded by CYP46A1) in the CNS, and transferred into the circulation, 25-
OHC is either a product of cholesterol autooxidation or created by enzymatic action of 
cholesterol-25-hydroxylase (CH25H) [188] or CYP27A1 [189]. 22R-OHC and 20R-OHC 
are formed in steroidogenic tissues as intermediates in steroid hormone synthesis [190]. 
Hh related oxysterols and their enzymatic synthesis are depicted in Figure 5.  
 
When trying to understand Ptch and Smo function it is important to take their 
cellular localization into account. In Drosophila, these two proteins cycle between 
internal endosomal compartments and the cell membrane [191] and their localization is 
regulated by the Hh ligand. In absence of Hh, Ptc is primarily localized in the plasma 
membrane where it acts by inhibiting the accumulation of Smo [137,192], by inducing 
conditions that favor the inward movement of Smo [193]. The binding of Hh protein to 
Ptc leads to an internalization of the Hh-Ptc complex through a dynamin-dependant 
endocytosis [194], and the complex is further targeted for degradation in lysosomes [195]. 
Being released from suppression by Ptc, Smo is then activated and translocated to the cell 
membrane. Smo has been shown to exists in both active and inactive forms, and is 
thought to be activated in a two step process [196–198]. In Drosophila, Smo activation 
involves PKA and CK1 mediated hyperphosphorylation of the cytoplasmic tail of Smo 
[199,200] and dimerization of Smo proteins. This dimerization is required for 
translocation to the membrane [201], and Smo mutants lacking the phosphorylation sites 
are defective in Hh signaling [199]. In contrast, vertebrate Smo lacks PKA and CK21 
phosphorylation sites [201], and several reports indicate that the kinase phosphorylating 
Smo in vertebrates is the GPCR kinase 2 (GRK2) [202–204].  
Hh signaling in vertebrates diverge from Drosophila in several ways, the most 
important being the requirement for the primary cilia in vertebrate Hh signaling [205–
210]. The primary cilium is a structure found in most eukaryotic cells that is about 3 M 
long. It consists of a basal body, one of the centrioles in the cell, and a microtubule shaft, 
called an anoxeme, that is enclosed by the cell membrane, sticking out from the cell like 
an antenna. The basal body and the daughter centriole is part of a larger structure that is 
called the pericentriolar material or the cetrosome. Mutations in intraflagellar transport 
(IFT) proteins involved in anterograde ciliary transport have been reported, resulting in 
phenotypes similar to Hh loss of function phenotypes [209,211,212]. The role of cilia 
seems to be specific for vertebrates. Hh signaling is impaired with the loss of the primary 
cilium in mammals and zebrafish, but not in Drosophila. The protein Iguana, which was 
originally implicated in the regulation of the Hh pathway in zebrafish, has been shown to 
have a role in ciliogenesis [213], and the loss of Iguana results in a lack of ciliary pit 
formation of and axonemal outgrowth [214]. In the absence of Hh ligands in vertebrates, 
Ptch is found in the membrane, where it is enriched in the shaft and around the base of 
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the primary cilium [215]. Ptch inhibits the phosphorylation and activation of Smo, thus 
preventing Smo from being translocated to the primary cilium where it can further 
activate the pathway [205,210,215–217]. Similarly to Drosophila, vertebrate Ptch is 
internalized when binding Hh ligands [215] and further processed for degradation [192]. 
Upon the release from Ptch suppression, Smo is phosphorylated, changes its 
conformation [201] and translocates from the endosomes and into the primary cilium 
[198]. Activated Smo associates with B-arrestin 2 (Arrb2), leading to endocytosis via 
clatrin coated pits [202], and Arrb2 may regulate Smo translocation to the cilia [218]. The 
translocation of Smo to the cilia is not enough to activate the pathway, supporting the 
idea that the Smo protein can exist in several forms, possibly in an inactive, a partially 
active and a fully active form [196,198].  
 
The differences in the Hh pathway between vertebrates and the invertebrate 
Drosophila lead to several questions about the evolutionary origin of this pathway. By 
evaluating the function and presence of different parts of the Hh signaling pathway across 
species, more light has been shed on its evolutionary origin. The Hh protein appears to 
have evolved from two separate proteins, the N-terminal “Hedge” domain and the C-
terminal “Hog” domain [219,220]. While evolutionary relatives of both Hedge and Hog 
have been identified in poriferans [219,220], cnidarians contain both a complete Hh gene 
and separate Hedge and Hog genes, indicating that the merge of these two genes into one 
Hh gene happened after the last common ancestor of these two phyla [219]. Amphioxus, 
which is a close relative to vertebrates contain a single Hh gene, called AmphiHh, 
indicating that the duplication of the Hh gene is specific to the vertebrate evolutionary 
tree [221]. AmphiHh is expressed in the notochord and ventral neural tube of amphioxus, 
similar to the expression of Shh and Shh-like proteins in vertebrates. According to one 
model, the Hh pathway evolved from a system that was controlling lipid homeostasis. In 
this system Smo is thought to have acted as a sensor of a lipid transported by Ptch, 
possibly cholesterol or a sterol derivative of cholesterol. Increased lipid levels could then 
have induced Smo mediated expression of Ptch, resulting in an increased efflux of this 
lipid from the cell [222]. The evolutionary fusion of the Hedge and Hog domains would 
further have provided the means for coupling of cholesterol to the Hedge protein, 
catalyzed by Hog, resulting in a Hh protein capable of blocking Ptch function. The 
earliest evolutionary relatives of Ptch are the RND permeases, which secrete hopanoids 
out of bacteria. Hopanoids are a sterol like class of molecules that are byproducts of 
bacterial metabolism. The nematode Caenorhabditis elegans lack homologues of Hh and 
Smo, but has three Ptch gene homologues, ptc-1/3 [223]. In addition as many as 24 ptc-
related (ptr) genes are present. The lack of Smo indicates that the nematode Ptch 
homologues may have retained a more ancestral role reminiscent of its evolutionary 



origin. The absence of ptc-3 in the nematode results in a late embryonic lethality due to 
an apparent defect in osmoregulation [223].  
 
The immotile primary cilia in eukaryotic cells were for a long time overlooked and 
believed to be a nonfunctional cellular equivalent of vestigial organs, evolutionary relics 
from unicellular flagellate ancestors that have lost the function that was retained in motile 
cilia. But while only a few cell types in the body have motile cilia, most eukaryotic cells 
have a primary cilium. The cilium has most likely developed as an extension of the 
eukaryotic cytoskeleton organized by the centrioles, and is now recognized as an 
important sensory organelle that communicates signals into the cell based on both 
mechanical and chemical stimuli in the environment. While the primary cilia are required 
for the hedgehog pathway in developmental processes [224], they also play an essential 
part in sensory cells in the adult body. Odorant receptors in the nose and fluid flow 
mechanosensors in the kidney localize to cilia, while gigantic modified cilia make up the 
photoreceptors in the eye [225]. The coupling of Smo function to the primary cilium is 
interesting in light of the sensory role of the primary cilia and the role of GPCR’s in 
mediating senses like taste, odor, vision and pain [226]. The characterization of the Hh 
pathway in planarians in comparison to the pathway in mammals and Drosophila has 
provided some insights into the merge of the Hh pathway and the cilium. In planarians, 
RNA interference mediated reduction of Cos2/Kif7, Fu or Iguana does not lead to 
measurable defects in the Hh pathway. In contrast, these proteins are essential for 
ciliogenesis in this organism [227]. These proteins may have been required for the 
assembly or function of motile cilia in an early eukaryotic ancestor. Further steps in the 
evolution of this pathway would then have been the association of Ptc, Smo and Gli with 
cilia, in addition to the loss of motility, resulting in immotile primary cilia with 
exclusively sensory capabilities. As a part of the ciliogenesis apparatus Cos2 and Fu may 
then have assumed roles in Hh signaling, and while the role of Fu have diminished in 
mammals, both Cos2 and Fu have been incorporated fully into the Hh pathway in 
Drosophila, with a following loss of primary cilia from fruit flies [228]. Drosophila Hh 
signaling is detailed in Figure 6, while vertebrate Hh signaling is detailed in Figure 7.  
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Figure 6. Hh signaling in Drosophila. A) In absence of Hh ligand, the Ptc receptor inhibits Smo from 
accumulating at the cell membrane by blocking STT4 kinase mediated P14P synthesis, by removing 
cholesterol and possibly by exposing membrane associated Smo to provitamin D3. Ptch may also inhibit 
Smo while cycling through the same endosome compartments as Smo. Inactive Smo is also 
inhibited/retained by Cos2. Cos2 acts as a scaffold for the Hh signaling complex (HSC), bringing Ci, Fu and 
the kinases PKA, CK1 and GSK3 together. Upon phosphorylation, Ci is targeted for cleavage and partil 
degradation in the proteasomes, resulting in the release of CiR that represses Hh target genes. In addition 
Sufu inhibits Ci by retaining it in the cytosol, and Sufu is possibly also a part of the HSC. B) Schematic of 
the signaling events in the absence of Hh. C) 1. Upon binding of the Hh ligand Ptc is internalized and 
degraded. 2. In absence of Ptch, STT4 kinase produces PI4P, and in addition cholesterol (and/or oxysterols) 
is allowed to accumulate, resulting in Smo activation. 3. Activated Smo alters the HSC activity, leading to 
the release of the uncleaved activator form of Ci, CiA. This is likely mediated by phosphorylation and 
activation of Fu (Fu*), which in turn phosphorylates and inactivates Cos2 (Cos2*) and Sufu, leading to a 
dissociation of the HSC from the microtubules. 4. In addition Smo is further activated (Smo*) by 
hyperphosphorylation, possibly mediated by Fu*/Cos2* complexes. 5. Smo* then accumulates at the cell 
membrane. 6. There it continues to recruit and activate HSC for the release of CiA. CiA is transfereed to the 
nucles where it induces transcription of target genes. In presence of Hh some of the activity of Smo may be 
due to activation of G-protein (not shown). D) Schematic of signaling events in the presence of Hh. Parts of 
the figure are modified from Stegman et al. 2004 [16], Aikin et al. 2008 [19], Jiang and Hui, 2008 [12], 
Wilson and Chuang , 2010 [9], Li et al. 2011 [11] and Goetz and Anderson , 2010 [18]. 
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4.3.3 The hedgehog signaling complex 
 
In both Drosophila and vertebrates the signaling downstream of Smo centers 
around the function of a signaling complex called the Hedgehog signaling complex 
(HSC). In Drosophila the HSC contains the serine/threonine kinase Fused (Fu), the 
microtubule or membrane tethered kinesin-like protein Costal2 (Cos2), and the 
transcription factor Cubitus interruptus (Ci) [229]. In absence of Hh ligand Cos2 tethers 
the HSC to microtubules and endosomal membranes [16], while recruiting protein kinase 
A (PKA), protein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3). PKA, and 
subsequently GSK3 and CK1 then phosphorylate C-terminal domain of Ci, targeting Ci 
for cleavage and partial degradation into a transcriptional repressor (CiR) that 
translocates to the nucleus to suppress target genes [230–235]. Phosphorylated Ci is 
bound by a protein called Supernumberary limbs (Slimb) [236], that is a subunit of an 
ubiquitin ligase complex that targets phosphorylated proteins or peptides for 
ubiquitination and proteosomal degradation [237]. Slimb catalyses the ubiquitination of 
the carboxyl terminus of Ci, targeting it for degradation by the proteasome. In absence of 
active Smo, the translocation of full length Ci to the nucleus is also prevented by a 
protein called Suppressor of fused (Sufu) that binds and sequesters Ci in the cytoplasm 
[238,239]. In resting cells a large portion of Ci is bound by Sufu, while the rest is bound 
in the HSC [240]. Some of the HSC’s in a cell may also exist as a non-microtubule-bound 
unit that interacts with Sufu [240,241], and binds to Smo [242]. In addition to its activity 
in the HSC, Cos2 is also thought to be involved in removing Smo from the plasma 
membrane, and sequestering Smo inside the cell [193].  
 
Upon the release from Ptch suppression mediated by Hh proteins, two key events 
occur, one being the phosphorylation, activation and translocation of Smo to the 
membrane, and the other being a change in the processing of Ci in the HSC. Yet several 
of the proteins in the Hh pathway have more than one role, and the complex interactions 
make it difficult to establish a defined timeline of the signaling events. Activated Smo is 
primarily thought to induce a change in the HSC through its interaction with Cos2 and 
Fu, leading to phosphorylation of Fu. Fu in turn phosphorylates and alters the activity of 
Cos2 and Sufu, preventing these proteins from blocking the release and nuclear 
translocation of CiA [240,243]. In contrast, Fu and Cos2 have also been implied in the 
activation of Smo [244], indicating that Cos2 could mediate an interaction between Smo 
and the HSC in both its inactive and active state. The release of Smo from Ptch 
suppression may induce a change in the interaction between Smo and Cos2 resulting in a 
switch of the activity of PKA and CK1 from Ci to Smo [19,242], resulting in 
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phosphorylation and further activation of Smo, while the uncleaved activating form of Ci 
(CiA) is released [240,245–247].  
 
 
 
There are also reports that Fu phosphorylation of Cos2 attenuates Cos2-Smo interaction 
and induces degradation of Cos2, releasing Smo from the suppression by Cos2 [244]. 
 
Figure 7. Hh signaling in vertebrates. A) In absence of Hh ligand, the Ptc receptor inhibits Smo from 
accumulating in the cilia, possibly by removing a sterol like lipid from the cell or from the ciliary 
environment. Ptch may also affect Smo while cycling through endosomes/vesicles containing Smo. In absence 
of active Smo, Gli is prevented from reaching the nucleus by Sufu, and Gli associates with a HSC possibly 
contain Kif7. Kif7 may recruit HSC’s to the base of the primary cilia, but in the absence of active Smo, the 
HSC releases GliR that represses target genes. The amount of HSC’s in the cilia in absence of Hh is low. B) In 
the presence of Hh, Ptch function is inhibited and Ptch is removed from the cilium by internalization into 
endosomes. This results in activation and translocation of Smo to the primary cilium, possibly involving Arrb2 
and Kif3a. The amount of HSC in the cilia increases, and in presence of active ciliary Smo the HSC releases 
GliA that activates transcription of target genes in the nucleus. In presence of Hh and activated Smo, the 
suppressor function of Sufu is also inhibited, and Sufu is ubiquinated and degraded, resulting in a lowered 
ability of the cell to retain Gli proteins in the cytosol. The involvement of cholesterol and other lipids like 
PI4P is not shown in this figure. Parts of the figure are modified from Wilson and Chuang, 2010 [9], Li et al. 
2011 [11], Goetz and Anderson, 2010 [18], Scales and de Sauvage, 2009 [22] and Rubin and de Sauvage, 2006 
[24].  
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Cos2 has been shown to have kinsein like motor function, being able to move along 
microtubules [248], but it remains to be shown whether Cos2 does mediates movement of 
Smo or the HSC along microtubule, or whether Cos2 only tethers he complexes to the 
microtubule.  
 
Table 1. Hedgehog pathway components in Drosophila and vertebrates (mouse) 
Drosophila gene Vertebrate (mouse) Function 
Hedgehog (Hh) Shh, Ihh, Dhh Secreted signaling ligand activating the Hh pathway 
Skinny hedgehog (Ski) Hhat (Skn) Acyltransferase involved in Hh ligand palmitoylation 
Dispatched (Disp) Disp1, Disp2 Transmembrane protein involved in Hh ligand release 
Smoothened (Smo) Smo Positive transmembrane transducer  
Patched (Ptc) Ptch1, Ptch2 Inhibits Smo translocation and activity, and possibly a sterol pump 
(cholesterol, provitamin D3). Also blocks STT4 kinase activity.  
Interference hedgehog 
(Ihog), Brother Ihog 
(Boi) 
Cdo, Boc Ptch co-receptors 
Costal-2 (Cos-2) Kif 7, (Kif family) Scaffold for Ci/Gli processing, positive and negative roles  
Fused (Fu) Fu (Stk36) Positive transducer required for Sufu and Cos2 phosphorylation 
Suppressor of 
fused (Sufu) 
Sufu Negative regulator of Ci/Gli proteins 
Cubitus 
interruptus (Ci). 
Gli1, Gli2, Gli3 Transcriptional activator and repressor of Hh target genes 
Dally, Dally-like 
protein (Dlp) 
GPC4, GPC6 Heparan-sulfate proteoglycan glypican involved in Hh movement 
and reception 
 
Tout-velu (Ttv), Sister 
of Ttv (Sotv), Brother 
of Ttv (Botv) 
Ext1-3 HSPG glycosylation (polymerization), involved in Hh movement  
 
Shifted (Shf) Wif Secreted protein involved in Hh movement 
Hedgehog-interacting 
protein (HIP1) 
HIP Negative regulator of Hh movement 
Protein kinase A 
(PKA) 
PKA Ci/Gli and Smo phosphorylation, positive and negative regulator 
 
Casein kinase 1 (CkI) CK1 Ci and Smo phosphorylation 
Shaggy (Sgg) GSK3 Ci and Smo phosphorylation 
Supernumerary limbs 
(Slimb) 
-TRCP F-box protein substrate recognition subunit of ubiquitin E3 ligase 
The table is modified from Jia and Jiang 2006 [7]. 
 
There are three vertebrate homologues of Ci, namely Gli1, Gli2 and Gli3. The 
three homologues seem to have adopted different roles that, when combined, overlap 
with the regulatory properties of Ci. Gli2 and Gli3 are the primary mediators of Hh 
signaling [49,50,249,250]. Similarly to Ci, Gli3 and to a lesser extent Gli2 [251] undergo 
proteasome-mediated cleavage of the carboxyl-end to repressor forms (GliR) in the 
absence of Hh ligands. The primary role of Gli3 is to act as an Hh regulated repressor of 
transcription in absence of Hh, while the primary role of Gli2 is to act as an activator of 
transcription in the presence of Hh [21,252]. However, Gli2 can act as a repressor and 
Gli3 can act as a activator in some developmental contexts [49,251,253–255]. The third 
member, Gli1 acts solely as an activator [49,50], and is an important transcriptional target 
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of activated Gli2. Gli1 repressor function has never been observed [50,256,257]. In 
absence of Hh signaling Gli3 is cleaved and represses transcription of target genes while 
Gli2 is degraded and thus unable to activate transcription, resulting in a lack of Gli1 
transcription [251]. Upon Hh pathway activation Gli3 is no longer cleaved and is thus 
unable to repress its targets, while Gli2 is translocated to the nucleus as an activator, 
leading to Gli1 transcription. Gli1 acts in a positive feedback loop, activating 
transcription of target genes, including itself. In support of the idea that the primary 
cilium is required for Hh signaling, not only Ptch and Smo, but Gli1, Gli2, Gli3 and Sufu 
are also trafficked through this organelle [196–198,212,215,216,258]. Like Ci in 
Drosophila, vertebrate Gli’s are also found in a HSC. In absence of Hh and active Smo, 
the Gli proteins are retained in the cytoplasm as a part of the HSC’s. In vertebrates this 
complex contains Fu, PKA, CK1, GSK3 and possibly the Cos2 analog Kif7 [259,260]. 
Gli2-3 is phosphorylated by PKA in four sites [251,261], which targets Gli2-3 for further 
phosphorylations by CK1 and GSK3 in a manner similar to Ci [232,234]. The 
hyperphosphorylated Gli proteins are then recognized by the Slimb homologue -TrCP 
[251,262] before ubiquitination and degradation is mediated, and the truncated N-
terminal repressor form is released. While the Slimb/-TrCP mediated ubiquitination of 
Ci/Gli2/3 leads to partial degradation, a E3 ubiquitin ligase system Hib/SPOP mediates 
ubiquitination that leads to complete Ci/Gli1 degradation [263,264]. Further a HECT 
family E3 ligase, Numb, promotes Itch-dependent ubiquitination and degradation of Gli1 
[265]. With the requirement for cilia in Hh vertebrate Hh signaling, it is interesting to 
note that proteasomes localize to the base of the primary cilium. While Gli proteins that 
are captured by the HSC are processed to GliR in the absence of Hh, the nuclear 
localization of unprocessed Gli proteins is prevented by Sufu [266–268]. In addition Sufu 
acts as a nuclear co-repressor that removes Gli from the nucleus [269–271]. Sufu may 
also interact with Arrb2, Kif3a and IFT88 [216], but the cilium does not appear to be 
required for the Sufu mediated inhibition of Gli function [258,272]. Thus, the role of Sufu 
may be to prevent newly formed Gli proteins from entering the nucleus, allowing Gli to 
be retained in the cytosol where it can bind HSC’s and be processed to a repressor. Thus 
Gli has to be processed through the cilia in order for Smo to inhibit Sufu [273], in order 
for Gli proteins to reach the nucleus. Gli protein activation is also prevented by other 
proteins; PKA can retain Gli1 proteins in the cytoplasm by phosphorylation of a PKA site 
in the nuclear localization signal peptide of Gli1 [274]. Upon binding of Hh to Ptch and 
the subsequent translocation of activated Smo to the cilia, HSC’s containing Gli2 and 
Gli3 accumulate in the cilia. The presence of Smo leads to changes in the processing of 
Gli proteins in the HSC. The Gli suppressor Sufu, for instance, is ubiquitinated upon the 
activation of Hh signaling [266] which initiates its proteasomal degradation [275] leading 
to the release of the activating forms of Gli2/3 (GliA). GliA proteins translocate to the 



nucleus to regulate transcription of downstream target genes including Gli1 and Ptch. The 
closely graded boundaries in early development also entail that the Hh pathway is not a 
on or off system, but that it can translate different Hh ligand concentrations and signal 
durations into various response levels.  
While the hedgehog pathway in vertebrates and fruit flies has diverged in the 
requirement for the primary cilium, there are also other important differences. The 
phosphorylation sites for PKA, CKI and GSK3 are conserved between Ci and Gli1-3 
[231,234] but in both mice and zebrafish the absence of PKA is enough to activate Hh 
signaling [276,277]. A recent kinase screen has identified Dyrk2 as a kinase that targets 
Gli2 for proteasomal degradation, while Dyrk2 in turn is modulated by MAP3K10 [278]. 
There are several Cos2 homologues in mammals in the family of Kif proteins, but a 
single Kif protein that functions like Cos2 has not been identified. While inactivation of 
Kif7 and Kif27 in cultured mammalian cells did not affect Hh signaling [279], in vivo 
studies still support that Kif7 is involved in the Hh pathway without interacting directly 
with Smo [259,260]. It is possible that several Kif’s overlap in function as regulators of 
the transport of Smo and other signaling components in the cilia, both in retrograde and 
anterograde ciliary transport. The roles of Fu and Sufu have also diverged between fruit 
flies and vertebrates. While Fu can inhibit the degradation complex [280], as well as 
phosphorylating and inhibiting Sufu [270], Fu knock-out mice does not display 
phenotypes of impaired Hh signaling in embryonic development [281,282]. Thus Fu 
function may be fully dispensable in vertebrates, although Fu function is essential for fly 
development [283]. In contrast, while Sufu knock-out has very mild phenotypes in the 
fruit fly [284], Sufu knock-out mice have phenotypes that correspond to full pathway 
activation, equal to Ptch knockout mice [285].  
Additional proteins that are not detailed here but that have been shown to affect 
Hh signaling are; Ren, a negative regulator preventing Gli translocation to the nucleus 
[286], Rab23, a Rab-GTPase vesicular transport protein that acts as a negative regulator 
of Hh signaling [287], Tectonic, a secreted glycoprotein that is required for both 
activation and inhibition of Hh signaling [288], Dyrk1, a kinase has been shown to 
enhance the transcriptional activity of Gli1 in the nucleus [289], MIM/BEG4, a actin-
binding protein that modulates Hh signaling by regulating Gli-dependent transcriptional 
activation [290] and Sil, a protein that may be involved in the Hh pathway downstream of 
Ptc [291]. Two protein families of Krüppel-like zinc finger proteins that are related to Gli 
transcription factors have been identified called the Zic protein family [292] and the Gli-
similar (Glis) protein family [293]. While Glis proteins regulate a number of 
physiological processes, and localize to the primary cilium, very little is known of how 
these transcription factors are regulated [293]. Members of the Zic protein family are 



homologues of the Drosophila protein Odd-paired, and are involved in development 
[292], in some contexts in conjunction with Gli proteins. In addition, there are some 
indications that Zic and Gli proteins interact physically [294]. Key Hh pathway 
components are listed in Table 1.  
 
4.3.4  Transcriptional targets of Hh signaling 
 
The Hh signaling response is mediated by the binding of the Ci/Gli1-3 
transcription factors to a Gli-consensus binding sequence, ‘TGGGTGGTC’ [295–298], in 
promoter and enhancer regions of target genes. The transcription factors act as both 
activators and repressors on the transcription of a number of genes that vary between 
organisms and tissues. There are several examples of graded responses to Hh signaling, 
often in conjunction with other signaling factors, including the establishment of the A/P 
boundary in wing disks and the tight segmental boundaries in Drosophila described 
above. In addition several response elements and enhancers, in addition to the Gli 
consensus sequence, may regulate the expression of each specific gene target. In 
Drosophila, Hh targets genes include Dpp, Wg, Ptch, Col and En [239,299]. Vertebrate 
targets include components of the pathway, Ptch, Gli1 and Hip, as well as several 
proteins from various protein families including BMP [300] HOX [300], FGF [301], Myc 
[302], Cyclin [303], VEGF [304,305], Angiopoietin [305,306], and other proteins 
including PDGFR [307], Bcl-2 [308,309], Bmi1 [310], Wnt [311], Hes1 [312], HNF-3b 
[298], SPOP [263]. GliR represses target genes when Hh is absent, and while moderate 
levels of Hh signaling leads to the de-depression these genes, higher levels leads to 
transcriptional activation. In mice, a total of 42 genes have two or more Gli consensus 
binding sequences in the enhancer regions [313]. There are also several Gli gene targets 
that act in feedback mechanisms on Hh pathway activity and the Hh protein. While Gli1 
mediates an important positive feedback signal, the expression of Ptch and Hip reduce the 
movement of Hh ligands and retrains Hh signaling in a negative feedback loop. Factors 
involved in movement and reception of the Hh ligands, like Ihog/Boi, Cdo/Boc and Gas1 
are down regulated in response to Hh signaling, also functioning as negative feedback to 
Hh pathway activation. 
4.4 Pathway interactions 
 
Several of the Gli gene targets mentioned above are involved in other signaling 
pathways, including the secreted ligands BMP, FGF, VEGF and Wnt that can activate 
their corresponding signaling pathways in the Hh active or surrounding cells. Hh 
signaling, in turn, is regulated and modulated by a wide range of other pathways, and the 
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multiple pathway interactions make up a signaling network that controls cell fate and 
differentiation. The evolution of such pathway interactions was key to the development 
of multicellular organisms, in which single cells were required to cooperate with and 
respond to neighboring cells, while taking on different roles. Signaling pathways that 
affect Hh signaling can be divided into two categories. The fist category is the pathways 
that induce expression of Hh ligands and the second, pathways that modulate the 
signaling cascade and especially the Gli transcription factors. Signaling pathways and 
factors that have been reported to activate Hh ligand expression, including Shh, are EGF 
induced PI3K/Akt [314], Ras [315,316], NFB pathway [317,318], p63 overexpression 
[319], ROR via -catenin and p300 [320], and ER activation [321]. Hh signaling and 
Gli protein activity is regulated and modulated by several other signaling pathways and 
factors, including RAS or RAS/MEK/AKT [322–324], PI3K/Akt [325], PKC/MEK-1 
[326], JUN [327], EGF/EGFR [328], Notch1 [329], and possibly Wnt/-catenin [330]. Hh 
signaling is reported to downregulate Wnt signaling in gastric cancer through expression 
of a Wnt signaling inhibitor SFRP-1 [331–333]. GLI1 expression is activated by the 
transcription factor EWS-FLI1 [334,335] while the protein product of the SCL/TAL1 
interrupting locus (SIL) is responsible for the de-repression of GLI1 [336]. The 
expression of Gli1 and Gli2 is also increased by SMAD3 mediated TGF signaling 
[337,338]. Tumor suppressors that negatively regulate Hh signaling are PTEN [323], p53 
[339], REN [286,340] and Numb [265]. Active Hh signaling inhibits p53 accumulation 
[339,341]. In light of the effect oxysterols exert on Smo, it is interesting to note that 
though OSBP and/or ORP proteins could be involved directly in the Hh pathway, they 
may also modulate Hh signaling by affecting signaling pathways that interact with the Hh 
pathway. In addition to regulating shingomyelin synthesis [342] and modulating insulin 
signaling in hepatic lipogenesis [343], mammalian OSBP also acts as a sterol-responsive 
regulatory scaffolding protein in the cytosol through its interaction with serine/threonine 
phosphatase PP2A and the tyrosine phosphatase PTPPBS [182], two phosphatases that 
regulate the activity of the MAPK/MEK targets ERK1 and ERK2. In addition, ORP9 
regulates of Akt phosphorylation [344], and the oxysterol binding protein BIP in C. 
elegans is involved in modulation of TGF-ß signaling [345]. Hh related pathway 
interactions in tissue repair and carcinogenesis are shown in Figure 7. 
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4.5 Hh pathway in disease and cancer 
 
The Hh pathway and proteins required for Hh pathway function are also behind 
several severe birth defects, disorders and diseases. Mutations that induce loss-of-
function in the human Shh gene, SHH, leads to a loss of the ventral midline and results in 
a disorder called holoprosencephaly (HPE) [346–349]. HPE phenotypes include cyclopia 
and impaired separation of the two halves of the forebrain. HPE is found in 
approximately 1/250 induced abortions and in 1/16,000 live births [350]. Mutations in 
 
Figure 8. Pathway interaction in tissue repair and carcinogenesis. A schematic representation of cellular 
events and signaling elements involved in the regulation of SHH expression, Shh dependant and independent 
GLI activation, and mediation of the Hh activation-induced cellular response. Potential cellular signaling 
elements involved in the regulation of SHH expression are indicated, including signals activated in response 
to growth factors and cytokines during tissue injury and regeneration, inflammation and cancer progression. 
Modified from Mimeault and Batra 2010 [8] 
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PTCH [351] and GLI2 [352] have also been linked to HPE-like phenotypes. Mutations in 
GLI3 are linked to Pallister-Hall syndrome [353,354], Grieg cephalopolysyndactyly 
syndrome [353,355], Postaxial polydactyly type A [356], Postaxial polydactyly type A/B 
[357] and Preaxial polydactyly type-IV [357]. The autosomal recessive Smith-Lemli-
Opitz syndrome (SLOS) [358,359] results in some phenotypes reminiscent of Hh 
mutations due to a defect in cholesterol biosynthesis that in turn affects Hh signaling. 
Bardet-Biedl syndrome [360], Joubert syndrome [361], Kartager syndrome [362] and 
Polycystic kidney disease [363] are tied to dysformation of cilia and also include 
phenotypes reminiscent of Hh pathway mutations. 
 
In addition to the disorders resulting from alterations in Hh signaling during 
development, the pathway is also involved in human disease in young and adult 
individuals. For instance, activation of the Hh pathway can modulate hair growth 
[84,364] and erectile dysfunction [365]. But the most prominent human disease involving 
the Hh pathway is cancer. The first link between the Hh pathway and cancer came when 
PTCH was identified as a tumor suppressor, based on mutations PTCH in an uncommon 
human disorder called nevoid basal cell carcinoma syndrome, or Gorlin syndrome [366–
368]. Patients who have the Gorlin syndrome are PTCH1 heterozygotes, and suffer from 
birth defects such as skeletal malformations. They frequently develop neoplasia and 
cancer [369,370] due to mutations that inactivate the remaining wild type allele of 
PTCH1. The PTCH heterozygosis predisposes patients with the Gorlin syndrome to 
various forms of cancers, including multiple basal cell carcinomas, medulloblastomas, 
ovarian fibromas, and with a lower frequency of occurrence rhabdomyosarcomas, 
meningiomas, fibrosarcomas and cardiac fibromas [370–372]. PTCH1 mutations have 
also been found to be associated with a number of sporadic tumors, and are found in up to 
40% or more of sporadic basal cell carcinomas (BCC) [373–376], the most common form 
of human cancer. BCC represents 1 out of 3 diagnosed tumors, and affects one out of six 
individuals in their lifetime [377]. Other sporadic cancers include medulloblastoma 
[376,378–380], squamous cell esophageal carcinoma [381], meningioma [382], 
transitional cell bladder carcinoma [383], benign skin trichoepitheliomas [384], and 
various noninflammatory cysts [385]. BCC is believed to be derived from stem cells in 
the bulge of the hair follicle, cells that have endogenous Hh signaling, and the various 
tumors mentioned above also arise from tissues that harbor endogenous Hh signaling. In 
addition to the inhibiting mutations in PTCH1, activating mutations in SMO have been 
found to be associated with medulloblastoma [386,387], as well as being identified in 
about 20% of sporadic BCC’s [386–388]. In addition, inactivating mutations in the SUFU 
gene have also been identified in BCC [389]. As PTCH1 and SMO mutations lead to 
GLI1 expression, it is not surprising that high GLI1 expression is a consistent feature of 
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tumors harboring such mutations [390,391]. This implies that the activity of GLI1, 
through its transcriptional targets, may be an important or prerequisite step for cancer 
development in the cells harboring PTCH1 and SMO mutations. Because GLI1 up-
regulation is a consistent finding in all BCC’s, transcriptional changes would seem to be 
the most likely mechanism by which the pathway affects tumorigenesis. The GLI1 gene 
was in fact discovered due to its gene amplification and high expression in gliomas [392]. 
GLI1 gene amplification has been reported in some lymphomas, and sarcomas [393,394], 
and the degree of GLI1 gene expression in sarcomas carrying GLI1 amplification 
correlates with tumor pathology [395]. 
 
In addition to the named tumors where Hh signaling appears to play a central role, 
abnormal Hh pathway activity has been implied in a broad spectrum of other human 
tumors, including brain [376,378–380,392], skin [366,367], liver [396], blood (leukemia) 
[397], lung [81], ovarian [398,399], breast [400–402], bladder [403], prostate [404,405] 
and gastrointestinal cancers [406] such as oral [407], esophageal, gastric, biliary tract 
[406] and pancreatic cancer [408]. In many of these tumors however, the cause of Hh 
pathway activation is not due to pathway mutations, but rather due to over expression of 
Hh ligands, and especially Shh [81,406,409]. There has been some controversy whether 
tumor derived Hh ligands act on the tumor by autocrine signaling or on the stroma by 
paracrine signaling, but the current understanding is that Hh ligands expressed by tumors 
can act by both paracrine [410–417] and autocrine mechanisms [81,82,406,408]. The 
involvement of Hh signaling in carcinogenesis is well documented [399,401,402,411–
413,416–419]. For instance, Shh acts at multiple stages during pancreatic carcinogenesis 
[420], and Hh activation is found in both early tumors and metastatic cancers in the 
pancreas and esophagus [410,421–423]. Transgenic mice with pancreatic specific 
expression of SHH or GLI2 develop pancreatic tumors [315,408], and similarly, in gastric 
and prostate cancers, Hh signal activation is associated with cancer progression 
[82,404,405,424,425]. The involvement of Hh signaling and GLI transcription factors in 
proliferation in a developmental context supports the idea that abnormal Hh activation 
may drive tumor cell proliferation. The relation between Hh activation in tumor cells and 
proliferation is very clear in BCC, and MB. For instance, the expression of an active Smo 
mutant, SmoM2 in mouse cerebellar granule neuron precursors results in formation of 
medulloblastoma [426]. There are also some reports that Hh signaling is involved in the 
maintenance of putative tumor progenitor cell proliferations [427,428] and possibly 
“cancer stem cells” [77,397,429–435]. In addition to its involvement in carcinogenesis, 
Hh signaling has also been coupled to tumor metastasis and invasiveness 
[82,323,425,436], and resistance to chemotherapy and radiotherapy [437–439]. One of 
the mechanisms for how Hh signaling is thought to be involved in chemotherapy 
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resistance is the stromal barrier around the tumor tissue resulting from paracrine signaling 
between tumor and stromal cells [437,440,441]. In support of this, a Hh inhibitor 
enhanced the delivery of chemotherapy in a mouse model of pancreatic cancer by 
modulating the vascularization of the stromal barrier [437]. Similarly, cyclopamine 
treatment led to increased cytotoxic effects of radiation and paclitaxel [442] and 
inhibition of metastasis in combination with gemcitabine [436]. Shh has also been 
implied in regulation of transmembrane drug transport, providing a possible explanation 
to the effect of combined therapy of Hh inhibition and chemotherapy [438,443]. While 
oxysterols have been found to play an important role in mediating Hh signaling, 
oxysterols have pro-oxidation and pro-inflammatory properties and may be involved in 
carcinogenesis [444].  
 
While it is evident that Hh signaling has an important role in carcinogenesis and 
tumor development, elucidating this role is complicated due to the involvement of 
additional signal pathways that affect and are affected by the Hh signaling pathway. A 
detailed genetic study of 24 human pancreatic cancers revealed an average of 64 genetic 
alterations, and most of these were point mutations. The alterations were found in a set of 
12 core cellular signaling pathways and processes that were genetically altered in 67- 
100% of the tumors [445]. In all of the 24 pancreatic tumors that were tested the 
researchers found alterations in the KRAS, Wnt/Notch, Hh and TGFß signaling pathways 
[445], pathways that are important in development and stem cell maintenance. In this 
setting it is difficult to name one of the pathways the main culprit; as the combined 
dysregulation of these core pathways may be a major feature of pancreatic tumorigenesis. 
In addition, the crosstalk between these core pathways is extensive, as discussed above, 
with one example being the deregulation of Ras signaling that leads to Shh expression 
and Hh pathway activation in pancreatic carcinogenesis [315].  
 
4.6 Natural and synthetic modulators of Hh signaling 

The first natural Hh pathway inhibitor that was identified, cyclopamine, has a very 
interesting history. In 1957 the United States Department of Agriculture started an 
investigation of a strange epidemic of cyclopic birth defects in sheep located in Idaho. 
Researchers found that the fatal birth defects were caused by a teratogen from the plant 
Veratrum californicum [446,447] (Figure 9) that had been indigested by ewes during the 
gestation period. Based on plant extracts, a steroid alkaloid was identified as the cause of 
the fatal birth defects, and it was named cyclopamine due to the cyclopia it induced in the 
lambs [448–451].  
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Evidence emerged that linked mutations in the Hh pathway genes to cyclopia 
[346,347,452], and shortly after the Hh pathway was identified as the biological target of 
cyclopamine [453,454]. In addition to cyclopamine and jervine, this plant also contains 
several toxic alkaloids [455,456], with veratridine as one example. It is interesting to note 
that V. californicum, and related plants have played a part of natural medicine among 
both Native Americans and medieval Europeans. The juice of the roots was used to 
poison arrows before combat, the powdered root was used as an insecticide [457], and 
plant decoctions were used by both men and woman as a contraceptive [458–460], were 
used to treat tumors in combination with another plant, Salvia dorii, and its teratogenic 
effect was known to the native Americans [457]. The plant has also been used to treat 
cold, infections, injuries and pains of various kinds. Among the Shoshone a decoction of 
the root was taken daily for three weeks to produce permanent sterility in woman 
[458,461,462]. The white false hellebore, Veratrum album, a European relative of V. 
californicum is also toxic and has been used in similar manners [463]. In China, a 
relative, V. unigram has been used as a last resort emetic (induction of vomiting) and 
 
Figure 9. Veratrum californicum at Silver Lake, Wasatch Mountains, Utah, identified 
by locals as Skunk Cabbage. In addition to the common name Skunk Cabbage, 
Veratrum californicum is also commonly called “Corn Lily” and “False Hellebore”. It 
has also been called Veratrum tenuipetalum. 
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expectorants (as a mucus thinner and cough medicine), and externally as insecticides 
[462,464]. As the highly toxic alkaloids are produced in growing plants of the Veratrum 
species, the Native Americans harvested the plant during its dormant stage in the winter 
when using it as a medicine. The levels of toxic constituents are lowest during the winter 
months when the toxic alkaloids are degraded and metabolized. Cyclopamine has been 
used extensively for in vitro cancer research and in several in vivo xenograft models with 
varying results. Oral cyclopamine can block the growth of UV induced BCC’s in Ptch+/- 
mice by 50%, as well as inhibiting the formation of new tumors [465]. Cyclopamine also 
reduces medulloblastoma development in Ptch+/- mice [466], and reduces growth of 
many cancer cell lines in nu/nu mice [82,323,408,467]. Yet cyclopamine can also cause 
cell death at doses that do not inhibit Hh signaling [413]. Cyclopamine has been stated to 
convert to veratramine in acidic conditions [468] and is poorly soluble in water. In 
treatment of gastric tumors, cyclopamine had a better effect when co treatment with 
antacid was given [469], consistent with the idea of cyclopamine being unstable in acid.  
Several derivatives of cyclopamine that have a higher potency, reduced instability 
and improved pharmacokinetic profiles have been identified, such as KAAD-
cyclopamine [470], IPI-609 [421], IPI-926 [471] and cyclopamine tartarate salt (Cyc-T) 
[472]. In addition to cyclopamine, other plant derived natural inhibitors of Hh/Gli induced 
transcription have also been identified [6,17]. These include pentacyclic triterpenes, such 
as betulinic acid, that inhibit Hh/Gli signaling [17] and sesquiterpenes like zerumbone, 
bisindole alkaloids like staurosporinone and arcyriaflavin C, and physalin B [6]. The 
natural and dietary alkaloids solasodine, solanidine, tomatidine also act as Hh inhibitors, 
but with a lower potency than cyclopamine [23]. These compounds are found in plants of 
the genus Solanum, including tomato and potato plants. Natural Hh inhibitors and 
synthetic Cyclopamine derivatives are shown in Figure 10. 
 Current Hh pathway antagonists and agonists can be classified according to what 
level in the pathway they modulate; at the level of Hh/Ptch interaction, at the level of 
Smo translocation and activation and at the level of Gli activation, nuclear translocation 
and transcription. Modulators acting at the level of Hh/Ptch interaction are the Hh 
inhibitor robotnikinin [473] and the Shh neutralizing antibody 5E1 [474]. 
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Antagonists acting at the level of Smo include cyclopamine [453], KAAD-
cyclopamine [470], IPI-609 [421], IPI-926 (Saridegib) [471], provitamin D3 [157], CUR-
61414 (HhAntag) [475,476], GDC-0449 (Vismodegib/Erivedge) [477–479], compound 5 
and Z [480], 2-amino-thiazole [24], Sant1-4 [14], Sant-75 [481], itraconazole [482], BMS-
833923 (XL-139) (http://www.exelixis.com/pipeline/xl139), PF-04449913 [483], LDE-
225 (Erismodegib) [484] and desmethylveramiline [485]. In addition inhibitors of 
cholesterol synthesis, such as statins [160], affect signaling between Ptch and Smo. 
Compounds that activate the hedgehog pathway by agonistic action on Smo are SAG 
[14], purmorphamine [486] and certain oxysterols [155,156]. 
Antagonists acting at the level of the Gli transcription factors are HPI1-4 [26], 
GANT58 and GANT61 [20], arsenic trioxide [487,488], and the natural inhibitors 
including physalin B that was mentioned above [6]. There are also compounds can inhibit 
Hh signaling through by targeting signal pathways that modulate Hh signaling. For 
 
Figure 10. The structures of natural Hh inhibitors cyclopamine, betulinic acid, tomatidine, solasodine, 
solanidine, zerumbone, staurosporinone, arcyriaflavin C and physalin are shown. The structures of the synthetic 
cyclopamine derivatives KAAD-cyclopamine, IPI-609 and IPI926 are also shown. Modified from Hosoya et al. 
2008 [6], Arai et al. 2008 [17], Lipinksi et al. 2007 [23] and Heretsch et al. 2010 [5]. 
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instance, the alcohol dehydrogenase 7 (Adh7) inhibitor JK-184 inhibits Gli-transcription 
factor activity in a dose-dependent manner [489], and Forskolin inhibits Hh signaling by 
activating PKA that in turn inhibits Gli transcription factors [490,491]. The TGF- 
inhibitor SB-431542 blocks TGF- induced Gli2 transcriptional activity. Structures of Hh 
pathway antagonists are shown in Figure 11 and 12. 
 
 
 
 
Figure 11. Structures of Hh pathway antagonists. While robotnikinin inhibits the Hh protein, the rest of the 
compounds are antagonists that block Smo function. Modified from Heretsch et al. 2010 [5] and Peukert and 
Miller-Moslin, 2010 [13]. 
 

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4.7 Clinical trials with Hh inhibitors 

The Roche/Genentech compound GDC-0449, discovered by Curis, and now 
named Vismodegib (trade name Erivedge) represents the first Hedgehog signaling 
pathway antagonist to gain U.S. Food and Drug Administration (FDA) approval (January 
30th 2012). Erivedge is a Smo antagonist, and is also the first drug approved for treatment 
of advanced metastatic BCC by the FDA. The drug is intended for patients with locally 
advanced BCC who are not candidates for surgery or radiation, and whose cancer has 
spread to other parts of the body. Erivedge has undergone a Phase I and a Phase II 
clinical trial for BCC treatment [478] prior to the FDA approval, and is also undergoing 
several clinical trials for diverse cancers, including metastatic colorectal cancer, advanced 
ovarian cancer, small-cell lung cancer, advanced stomach cancer, pancreatic cancer, 
medulloblastoma and chondrosarcoma. The phase I trial for BCC treatment included 33 
patients, 18 with metastatic BCC and 15 with locally advanced BCC. Of the 18 patients, 
8 had confirmed partial responses, 1 patient had an unconfirmed partial response, 7 
patients had stable disease as best response and 2 patients had progressive disease, and 
the overall response rate was 50%. In the 15 patients, 2 had complete clinical responses, 7 
patients had partial responses, 4 patients had stable disease as the best response and 2 
patients had progressive disease, with an overall response rate of 60%. Erivedge 
displayed a favorable pharmacokinetic (PK) and pharmacodynamic (PD) profile, and no 
grade 5 adverse events were observed. The most common side effects in Erivedge treated 
patients include muscle spasms, hair loss, weight loss, nausea, diarrhea, fatigue, distorted 
 
Figure 12. The structures of Hh pathway agonists purmorphamine and SAG and structures of Gli antagonists 
GANT58, GANT61 and HPI-1-4. Modified from Heretsch et al. 2010 [5], Chen et al. 2002 [14], Lauth et al. 
2007 [20] and Hyman et al. 2009 [26]. 

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sense of taste, decreased appetite, constipation, vomiting and loss of taste. The clinical 
data from Erivedge treatment demonstrates that Hh inhibitors can be used to improve 
cancer treatment. As an example a case report from the treatment of a medulloblastoma 
patient can be highlighted. In April 2008 a 26-year-old male patient with widespread 
systemic metastatic medulloblastoma that was refractory to multiple therapies began 
treatment with Erivedge. By June the same year the patient’s pain score had been reduced 
from 8 to 0 on a 10-point scale, and the tumors had regressed rapidly, despite the heavy 
tumor burden and the extent of metastasis at the beginning of the treatment. This 
regression was transient, however, with a regrowth detected in July, and after a rapid 
progression of the disease the patient died in September, the same year [492]. Further 
studies showed that a mutation causing an amino acid substitution in the Smo protein had 
rendered the cancer cells resistant to the Erivedge treatment [414].  
The Infinity Pharmaceuticals compound IPI-926 (Saridegib) is a semi-synthetic 
cyclopamine derivative [471]. Saridegib is synthesized based on cyclopamine extracted 
from harvested V. californicum, and is currently undergoing clinical trials for the 
treatment of various types of cancer, including myelofibrosis and chondrosarcoma. 
Infinity recently ended a Phase 1b/2 clinical trial where patients with previously untreated 
metastatic pancreatic cancer had been treated with a combination of Saridegib and 
Gemcitabine. In the Phase 1b portion of the study, partial responses were observed in 5 of 
16, or 31%, of patients treated with three different dose levels of Saridegib (Infinity 
Pharmaceuticals press release). The Phase 2 double blind, randomized, placebo 
controlled trial comparing a Saridegib/Gemcitabine combination to placebo/Gemcitabine 
treatment was ended as preliminary data showed a difference in survival favoring the 
placebo/Gemcitabine arm due to a higher rate of progressive disease in the 
Saridegib/Gemcitabine arm of the study.  
Other Hh antagonists that are under evaluation in clinical trials, but that have not 
progressed as far as Erivedge and Saridegib, include the Novartis compound LDE-225/ 
Erismodegib and LEQ506, the Exelixis/Bristol-Myers Squibb’s BMS-833923 (XL139), 
the Millennium Pharmaceuticals’s TAK-441, and Phizer’s PF-04449913. In addition the 
Maastricht University Medical Center is performing a clinical trial using Vitamin D3 
(from a search in March 2012; http://www.clinicaltrials.gov/ct2/results?term=Hedgehog). 
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5. Aims of the study 
 
The Hh signaling pathway is a key regulatory pathway involved in human 
development and disease. Abnormal activation of this pathway due to mutations or 
overexpression has been identified in several human cancers. Many natural and synthetic 
inhibitors of this pathway have been identified, including the plant derived cyclopamine, 
and while some of these inhibitors have progressed to clinical trials, one of them have 
been approved for advanced BCC treatment by the FDA. While it is known that 
oxysterols and sterol metabolism are involved Hh signaling, the mode of action of the 
oxysterols in relation to the proteins Ptch and Smo are not fully understood. Reliable 
identification of specific oxysterols is challenging in biological samples, and especially in 
the small cellular samples used in standard in vitro cell based assays. 
 
The aim of this thesis has been divided into three core aspects; a caracterization of a new 
Hh antagonist, a study of natural Hh antagonists and a study of Hh pathway mechanisms 
with a focus on oxysterols. These focus areas can be divided into these aims: 
  
 Identify cyclopamine in Veratrum album. 
 Analyze the weakness and strengths of cyclopamine as an Hh inhibitor. 
 Characterize a novel SMO antagonist, and investigate the in vitro and in vivo 
properties of this agonist against tumor growth.  
 Develop a reliable technique for identifying and detecting oxysterols in small 
cellular samples, and use this technique to further elucidate the role of oxysterols 
in the Hh pathway and cancer.  
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6. Summary of results 

6.1 Paper I 

Based on the knowledge that the native population in America and Europe has 
used plants of the Veratrum family extensively in natural medicine, we proceeded to 
investigate Veratrum album, a species growing Norway, for the presence of cyclopamine. 
Using dried benzene extracts from the root of a subspecies of V. album (ssp. Virescens 
Gaudin) we investigated whether it could inhibit Hh pathway activity in vitro. In a 
standard Hh assay, using Shh-Light2 cells treated with Shh conditioned medium, we 
found that the extracts had a 50% inhibitory effect at a dilution of 1:50,000. The initial 
Mass spectrometry (MS) analysis revealed substantial amounts of what appeared to be 
cyclopamine, but some of the MS/MS fragments that were seen when analyzing control 
samples of commercially available cyclopamine was lacking in the analysis of the 
extracts. This was first believed to be due to performance variations with the MS 
instrumentation, but when the samples were analyzed on a shallower liquid 
chromatography (LC) gradient, it was evident that the compound derived from V. 
album ssp. viriscens had a shorter retention time than cyclopamine. To confirm these 
findings, the plant extracts were spiked with cyclopamine, and the analysis revealed two 
distinct peaks. As this unknown compound had the same mass, and a very similar 
retention time when compared to cyclopamine, we believed that what we had detected in 
the plant extracts was an isomer of cyclopamine. The shorter retention time in the reverse 
phase LC indicated that the potential cyclopamine isomer had slightly less hydrophobic 
properties when compared to cyclopamine, possibly due to the presence of an additional 
hydrophilic functional group. The compound was isolated for further elucidation of its 
structure, properties and biological activity. The compound was diluted with D2O, and 
analysis revealed that the deuterated compound had a 1 Da higher mass than deuterated 
cyclopamine, implying that the compound had an extra hydroxyl group compared to 
cyclopamine. 13C NMR data supported the presence of a hydroxyl group, and the 
presence of an aromatic ring was confirmed by UV spectroscopy. The presence of the 
aromatic ring corresponded with the limited MS/MS fragmentation in the isomer 
compared with cyclopamine. As cyclopamine has been previously reported to convert 
into veratramine, and as veratramine contains an aromatic ring, the 13C NMR data of 
veratramine and the isolated compound was compared. Only six aromatic resonances 
were found in the compound while eight was present in veratramine. Based on the 
interpretation of different NMR spectrums (one dimensional 1H, 13C APT, HSC, HMBC 

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and NOESY), the isolated compound was identified as dihydroveratramine (DHV). To 
our knowledge, DHV has not previously been reported as a natural product. We are 
confident that DHV was present in the plant, and that it was not a product of reduction of 
veratramine during sample preparation. DHV was detected by LC-MS directly in the 
crude benzene extract, and a reduction of the double bond in veratramine would be an 
energetically non-favorable process under the conditions of the isolation procedure. The 
isolated DHV inhibited Hh signaling with an IC50 of 8 μM in Shh treated cells and an 
IC50 > 10 μM in SAG treated cells. In comparison, cyclopamine had an IC50 of 0,3 μM 
in Shh treated cells and an IC50 of 2 μM in SAG treated cells. Approximately 4% (w/w) 
of the benzene extract was measured to be DHV. We have demonstrated that VA does 
not contain cyclopamine, but DHV, a molecule that is easily mistaken for cyclopamine. 
Both of these molecules have the same molecular formula and mass and similar retention 
times. The mass fragmentation spectra for these molecules are similar, and the main 
fragmentation product is the same for both molecules.  
6.2 Paper II 

In light of the cyclopamine isomer identified in V. album and the reported acid 
instability in cyclopamine, a sample of cyclopamine was exposed to an acidic 
environment, and selected ion monitoring (SIM) and total ion current (TIC) 
chromatograms of acidified cyclopamine were generated using capillary LC-TOF-MS. A 
steep LC gradient similar to one used for PK studies of cyclopamine was employed, and 
cyclopamine was eluted within a relatively short time (6.5 min) and a single peak 
appeared in the generated chromatogram. In order to improve the resolution a shallower 
LC gradient was also used, and two partially co-eluting peaks with the same m/z value as 
cyclopamine appeared for the acid treated cyclopamine. It was believed that the two 
peaks were acid induced isomers of cyclopamine. The peak area of these isomers 
constituted about 40% of the total peak area. It was assumed that the peak area ratio was 
the actual ratio, and the ratio of the two peaks was not altered within a period of 24 hours, 
or when the solution was neutralized or basified. In contrast cyclopamine that had not 
been exposed to an acidic environment appeared as a single peak using the shallower 
gradient. The isomerization was not seen in non-aqueous, acidic solutions. After 5 days in 
an aqueous environment a slow reversion was observed, and approximately 1/5 of the 
peak area of the isomers reverted to cyclopamine. In order to investigate if cyclopamine 
would isomerize when exposed to stomach acid in vivo, we analyzed plasma from mice 
that had received cyclopamine by PO administration. Isomers were present in the plasma 
4 h after administration, demonstrating that exposure to stomach acid will cause 
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structural alterations in cyclopamine. It is likely that the in vivo detected isomers are the 
same as those detected in vitro, but an elucidation of the isomers in the plasma by NMR 
was not possible. The isomers were not detected in the plasma when cyclopamine was 
given intraperitoneally (IP), supporting the idea of a stomach acid induced isomerization. 
As previous reports suggest that cyclopamine converts to veratramine in an acidic 
environment, the mouse plasma samples were also examined for the presence of 
veratramine, but no peak corresponding to veratramine was detected. The isomers were 
extracted from an acidic cyclopamine solution using a preparative LC-UV method. In this 
preparative method the isomers co-eluded completely. The structure of the isomers in this 
mix was determined using NMR and computational techniques, and the identified 
isomers were named cyclopamine (S) and cyclopamine (X). Cyclopamine (X) was less 
abundant relative to (S) (0.67:1) in the mixture, and no regular cyclopamine was detected. 
Therefore, it is assumed that the smallest of the partially co-eluding peaks in the LC–MS 
chromatogram is cyclopamine (X). The (S) isomer has an inverted configuration at 
carbon atom 23 as compared to cyclopamine, which has R configuration at this position. 
Quantum chemical calculations confirmed the NMR signal assignment and helped to rule 
out other possible isomerization products by comparing the calculated and the 
experimental 13C chemical shift spectra. Using Shh-Light2 hedgehog reporter cells, we 
investigated whether cyclopamine (S) and (X), retained cyclopamine’s antagonistic effect 
on the Hh pathway. Cyclopamine inhibited Hh pathway activation in Shh induced Shh-
Light2 cells by 75% at a dose of 1 μM. Contrasting this effect the extracted isomer mix 
did not display a statistically significant antagonistic effect to Hh signaling at a 
concentration of 1 μM. This was confirmed in a dose response assay where natural 
cyclopamine had a classical S shaped drop in activity and a relative IC50 of 250 nM. In 
contrast, a non-S shaped gradual drop of Hh pathway activity was exhibited by the 
combined cyclopamine isomers (S) and (X) with a relative IC50 of 2.25 μM. Thus the 
antagonistic activity of the isomers is an order of magnitude lower than seen with natural 
cyclopamine. It was not determined whether the weak activity that was detected was due 
to the isomers or whether it was due to a partial reversion to cyclopamine. As 
cyclopamine (S) and (X) does not block Hh signaling effectively, we investigated at 
which stage of the Hh pathway the inhibition is lost. Even through natural cyclopamine 
blocks Hh signaling by binding and inactivating Smo, it also induces the transport of this 
inactive form of Smo into the primary cilium where it is enriched. Thus, when Shh-Light-
2 cells were treated with either Shh or 1 μM natural cyclopamine, increased ciliary 
presence of Smo was observed as expected. The isomers lacked this activity, 
demonstrating the absence of bioactive potential. In conclusion, pH-induced cyclopamine 
isomerization abolishes the potential of the molecule to inhibit Hh signaling at the level 
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of SMO, and provides a mechanistic understanding for the reduced efficiency of natural 
cyclopamine in an acidic environment. 
6.3 Paper III 

A compound (2-bromo-N-(4-(8-methylimidazo[1,2-a]pyridin-2-yl)phenyl)- 
benzamide) with an IC50 of 100 nM in Shh-L2 cells was identified and named MS-0022. 
In comparison, cyclopamine had an IC50 of 210 nM whereas GDC-0449 had an IC50 of 
30 nM using the same conditions. The structure-activity relationship of MS-0022 was 
explored using two sets of closely related MS-0022 analogs. All of the analogs had a 
lower activity than MS-0022, and while some structural alterations led to large drops in 
activity, some alterations were tolerated (see Paper III for a full description). MS-0022 
was shown to compete with BODIPY-Cyclopamine for binding to Smo (IC50 = 259 nM), 
and effectively inhibited Hh signaling in Shh-Light2 cells activated with Shh, SAG and 
activating oxysterols (OHC-20 and OHC-22S in combination). In addition MS-0022 
reduced Gli1 mRNA expression in the mouse embryonic fibroblast (MEF) cell line Ptch-
/- (based on Ptch-/- knockout mice). While cyclopamine induced translocation of inactive 
Smo to the cilia, MS-0022 blocked ciliary accumulation of Smo similar to GDC-0449. In 
contrast to cyclopamine and GDC-0449, MS-0022 reduced Gli1 mRNA expression by 
50% in Sufu -/- MEF cells at a dose of 10 μM. MS-0022 did not block the activity 
induced by Gli1 and Gli2 overexpression, but effectively blocked the effect of Shh 
stimulation on Gli1 and Gli2 overexpressing cells. At a dose of 20 μM, MS-0022 did not 
reduce nuclear Gli1 translocation in Sufu -/- cells, but the total level of Gli1 in the cells 
was reduced, correlating well with the reduction in Gli1 mRNA. MS-0022 reduced 
growth and Gli1 mRNA expression in cancer cell lines PANC-1, SUIT-2, PC-3 and 
FEMX in a varying degree, and at lower doses the growth inhibition and reduction in 
Gli1 mRNA did not correlate for all of the cell lines. However, at a dose of 10 μM MS-
0022, the reduction in Gli1 mRNA expression correlated with growth reduction across 
the four cell lines, compared to a control cell line. This is consistent with an additional 
Hh pathway inhibitory effect of MS-0022 downstream of Smo/Sufu that requires relative 
higher doses of the compound as compared to direct Smo inhibition. MS-0022 reduced 
growth from 40% to 70% in these four cell lines at 10 μM, while GDC-0449 and 
cyclopamine had a maximum of 30% growth inhibition at the same concentration. MS-
0022 reduced the number of large and medium sized colonies in a soft agar colony assay 
in a dose dependent manner. While the number of large and medium size colonies 
decreased, the number of small colonies after MS-0022 treatment increased, indicating 
that the reduced growth is due to decreased proliferation rather than apoptosis. Long-term 
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growth assays further confirmed the efficacy of this compound. MS-0022 did not 
significantly block Wnt signaling or NFkB signaling at doses up to 20 μM, indicating 
pathway specificity towards the Hh pathway. MS-0022 led to a slight increase of NFkB 
signaling, but did not inhibit the activity of any of a panel of 58 Kinases (Millipore 
diversity panel). 
 The PO availability of MS-0022 as calculated to be 98% and the half-life in mouse 
plasma was 55-60 minutes, indicating a moderate stability. The compound was well 
tolerated in mice upon IP administration of 200 mg/kg for 5 days, and IP administration 
of 50 mg/kg for 30 days. The animals did not show any outward signs of toxicity or other 
side effects (weight loss, fur ruffling, hunched posture). Upon the longer exposure, the 
AST/ALT levels remained greater than 1. PANC-1 xenografts were established in mice 
and the animals were treated for 30 days with control solvent or 50 mg/kg MS-0022 IP in 
a 5-day injection/2-day pause scheme. At the end of the treatment there was a 38% 
reduction in tumor volume in MS-treated animals compared to the control, but the growth 
appeared to be delayed transiently as the growth curves had the same shape towards the 
end of the experiment. No reduction in human or mouse Gli1 mRNA expression could be 
detected at the end of the experiment in the treated tumors compared to the control. In 
mice xenografted with SUIT-2, similar data was observed. However, after only seven day 
of MS-0022 PO treatment, Gli1 mRNA expression was reduces in the mouse stromal 
cells in the tumors. After 18 days of treatment this effect on stromal Gli1 expression was 
not observed. In the treated SUIT-2 xenografts, similarly to the PANC-1 xenografts, a 
transient delay of growth was observed during the first days of treatment, followed by a 
recovery of growth with growth rates in the treated group becoming similar to untreated 
tumors. Due to substantial variability in the SUIT-2 tumor, no apparent difference 
between the vascularization of samples derived from treated and untreated animals was 
detectable. Irrespective of MS-0022 treatment, CD31 staining revealed high 
vascularization at the tumor edge, while vascularization in the center of the tumor was 
generally low. In conclusion the identified compound, MS-0022, acts at the level of Smo, 
blocking its ciliary transport in the nanomolar range. An additional inhibitory effect of on 
Hh signaling downstream of Sufu that required a dose in the 10–20 micro molar range is 
linked to a reduction of Gli1 protein levels. MS-0022 transiently inhibited PANC-1 and 
SUIT-2 tumor growth, and displayed good pharmacokinetic properties and no apparent 
toxicity.  
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6.4 Paper IV 

The oxysterols that activate the Hh signaling pathway, 20-OHC, 22S-OHC, 24S-
OHC and 25-OHC have very similar structures. Reliable identification of these, and other 
similar oxysterols, is very challenging and requires an effective separation step. They 
share the same molecular mass and mass fragmentation and have very similar logPs. In 
addition the potential autoxidation of cholesterol present in cells may contaminate 
oxysterols of cellular origin. After failing to separate oxysterols isomers by a previously 
established method, a new method was developed that provided the selectivity necessary 
to separate the isomers with enough resolution for quantitative determination. Under well 
separating conditions, the oxysterol analytes eluted as rather broad peaks (in both 
samples and standards), and we speculate that the derivatized oxysterols elute as mixtures 
of stereoisomers, and this was supported with 13C NMR experiments. Due to their neutral 
charge, oxysterols are difficult to detect with ESI-MS. Therefore, a “charge-tagging” is 
appropriate, and this was achieved using a Girard T reagent in large excess. Several 
challenges were overcome in in order to improve oxysterol separation and detection in 
the development of the described methodology (Paper IV). Cells were lyzed/precipitated 
directly in ice-cold ethanol, pipetted vigorously and frozen. Samples were then 
evaporated to dryness, and all of the following sample preparation steps were performed 
in the same tube. The reaction mixture containing tagged oxysterols, excess Girard T 
reagent, precipitates and particulate cellular matter was injected directly onto the SPE-LC 
system. An automated filtration/filter backflush (AFFL) technique was used in order to 
avoid filter clogging, and the loss of oxysterols across the AFFL system was <1%. In 
comparison, upon spin filtration of the sample before loading into the separation system 
there was a poor recovery of oxysterols (<1%). Although large amounts of Girard T were 
injected, the hydrophilic reagent was not retained by the reverse phase SPE enrichment 
column employed, and was flushed to waste without entering the separation column and 
the MS instrument. When employing automated AFFL-SPE-LC, only ~10 minutes of 
total manual effort (i.e. pipetting) per ~20 cell lysates was needed. The method was 
evaluated for the analytes 22S-OHC, 24S-OHC and 25-OHC, and the range was linear 
for the standards and spiked cell samples (0.2-33 nM vial concentration, 8-1400 pg 
injected). Even though 20-OHC was initially also monitored, it was not detected in the 
cell samples tested, and was not included in the final evaluation of the method. The 
within-day and between-day precisions, calculated as relative standard deviation, for low, 
medium and high levels of analytes was in the range of 5-19%, and the recovery for 
spiked lysate samples were 105-109%. In-vial sample intactness was good as samples 
produced equal peak areas 0-12 hours after first injection. Importantly, in the described 
methodology, autoxidation during lysis/sample preparation was not an issue for our 
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analytes, as oxysterol products of a heavy (13C) cholesterol control present in the lysis 
buffer were monitored for and were for all practical purposes absent. The retention time 
was constant and the SPE and LC columns held pressures of ~50 and ~150 bar after the 
implementation of AFFL-SPE-LC and did not need replacement during the study. As an 
initial sensitivity test, the oxysterol analytes were assessed in cell lines NIH3T3, Shh-
Light2, Ptch-/-, Sufu-/-, HEK293 (a human embryonic kidney cell line), HCT15 and 
HCT116 (human colon cancer cell lines). All tested human cell lines contained clearly 
detectable levels of 22S-OHC, 24S-OHC and 25-OHC, while oxysterol levels in mouse 
fibroblast cells were significantly lower, with 24S-OHC being under the detection limit in 
Sufu-/- and NIH3T3 cells, and 22S-OHC being undetectable in Sufu-/- cells. Flasks, vials, 
solutions and medium were not found to be sources of oxysterol contamination within the 
method’s LOD. In order to identify whether the technique could be used to detect 
differences in oxysterols between small cell populations, the heterogenic pancreas 
adenocarcinoma cell line BxPC3 was sorted into vimentin positive (vim+) and negative 
(vim-), vimentin being a marker for epithelial to mesenchymal transition (EMT). Only 
330,000 cells per population were tested by AFFL-SPE-LC-MS (n =2 for both vim + and 
vim -), and the vim+ cells showed clearly higher levels (150 ±25 pg/100,000 cells) of the 
oxysterol analyte 24S-OHC compared to vim- cells (58 ± 20 pg/100,000 cells). It remains 
to be seen whether the detected alterations of 24S-OHC in a subpopulation of BxPC3 
cells are of functional relevance, however, the reliability and sensitivity of the here 
described AFFL-SPE-LC-MS methodology opens for a future detailed analysis of 
oxysterol levels in small cell populations, and thus will be able to contribute to an 
improved understanding of this important group of metabolites. As oxysterols are 
involved in Hh signaling, we exposed a colon cancer cell line, HCT-116 to an Hh 
antagonist, MS-0022 at 5 μM. When treated 24 hours prior to lysis, the cells showed a 
significant ~3-fold decrease of 24S-OHC levels. Although the underlying mechanism 
behind this effect is unclear, these initial observations encourage further studies.  
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7. General discussion 
 
In the previous decades, the key aspects of cancer treatment have been the use of 
resection, radiation, chemotherapy or combinations of these to battle this deadly disease. 
Both chemotherapy and radiation targets one of the inherent abilities of cancer, the aspect 
of uncontrolled growth, proving valuable tools in cancer treatment. But where one type of 
cancer responds well to a certain treatment, other types quickly develop resistance, or re-
grow after an initial treatment response. As our understanding of cancer has increased 
there has been an intensified focus on targeting the signal pathways that the cancer cells 
depend on for their aberrant abilities. The discovery of the plant derived teratogenic 
compound cyclopamine was one of several discoveries that played a part in shifting the 
focus of cancer therapeutics from treating uncontrolled growth, to targeting the abnormal 
signaling pathways that underlies the uncontrolled growth and other properties of cancer 
cells. As summarized in the section “aim of this study”, the research summarized in this 
thesis has focused on three areas related to inhibition of the Hh signal pathway. The first 
area of focus has been the natural plant derived Hh antagonist cyclopamine, with isomers, 
combining cell signaling biology with high-resolution analytic chemistry. The second 
area of focus was the identification and characterization of a Smo antagonist. The third 
area of focus was on the role of oxysterols in pathway mechanisms and in preparation of 
this kind of study the development and testing of a method for measuring oxysterols in 
small cellular samples.  
 
We describe here (Paper I) the identification of dihydroveratramine (DHV) in V. 
album growing in the botanical garden in Oslo, Norway. To our knowledge DHV has not 
been detected as a natural product previously. However, the synthesis of DHV by 
reducing veratramine using H2 gas and a Pt catalyst was reported as early as in 1940 
[493]. In addition, DHV was later studied for its activity as a cardiac anti-accelerator 
[494]. As DHV was detected by LC-MS directly in the crude benzene extract form the 
plant root, we are confident that this compound was present in the plant and not a product 
of the isolation process. Also, a reduction of the double bond in veratramine would be an 
energetically non-favorable process under the conditions of the isolation procedure. We 
were not able to detect cyclopamine in V. album contrary to a previous report [495]. 
Another subspecies of the plant was used in this study, so we cannot rule out differences 
between the subspecies of V. album. In addition DHV is very easily mistaken for 
cyclopamine in L-MS analysis. Both of these molecules have the same molecular 
formula, mass and similar reverse phase retention times. The mass fragmentation spectra 
for these molecules are also very similar, with the main fragmentation product being the 
same for both molecules. DHV possessed an in vitro Hh inhibitory effect that was about 1 
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log lower than the activity of cyclopamine, and failed to induce translocation of Smo to 
the cilium. When comparing the Hh inhibitory action of the crude benzene extracts with 
the activity of the isolated DHV, it is evident that there may be other compounds in this 
plant that affect the hedgehog pathway. As the extract inhibited Shh induced signaling 
stronger than SAG induced signaling, similarly to cyclopamine, the Hh inhibitory activity 
in the extract likely acts on Smo. A DHV precursor or one or more DHV/cyclopamine 
related compounds that have a higher potency towards the Hh pathway could be present 
in V. album. While V. album has been a part of nature medicine in the past, it is still in 
use in “alterative” medicine today. In light of the Hh inhibitory activity identified in this 
plant, the medical use of this plant is highly questionable. Yet, V. album is still found in 
some commercial products. One product containing V. album, along with other plants, 
which has been marketed as an “infantile cholic remedy” has recently (2010) been 
associated with apparent life threatening events among infants [496].  
 
Issues with poor solubility in water and early reports that cyclopamine converted 
to veratramine in an acidic environment [497] has led to the development of different 
derivatives. In contrast to the previous reports we found two previously undetected 
isomers (S and X) of cyclopamine instead of veratramine after treating cyclopamine with 
acid (Paper II). The isomers can easily be mistaken for active natural cyclopamine when 
analyzed by standard LC–MS analysis conditions. In pharmaceutical analysis it is 
common to use short analysis times, and a steep solvent gradient. However, only when 
using a slower, shallower (and hence higher resolving separation) gradient it was possible 
to reveal a large degree of isomerization of natural cyclopamine as a result of 
acidification. A mechanism for the acid induced isomerization is proposed, including a 
ring opening and either a cyclization or an elimination of water, and the isomerization is 
believed to be reversible. The reappearance of original cyclopamine in an aqueous (S/X) 
solution indicates the existence of a thermodynamic equilibrium between at least two 
forms. From a chemical point of view the first step in this back reaction, hydratization of 
one of the double bonds in the conjugated double bond system, seems less likely. So our 
conclusion at this stage is that the R and S forms of cyclopamine do indeed freely 
isomerize between themselves in acidic water solution, however the kinetics of this 
transformation is not fast; chromatography of the isomers the same day after isolation did 
not show traces of regular cyclopamine. The isomerization appears to occur in vivo as 
isomers were detected in serum samples after per oral administration of cyclopamine in 
mice. IP administration of cyclopamine did not result in isomerization in vivo, supporting 
the idea of a stomach acid induced isomerization. During the study, our group detected 
only marginal/less than detectable amounts of veratramine after acidification 
of cyclopamine. This agrees with an earlier report [495], but is in disagreement with 
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Keeler [498], where the evidence for the conversion to veratramine is based on IR 
spectroscopy and thin layer chromatography (TLC). We speculate that the IR spectrum 
of cyclopamine (X) is similar to that of veratramine, since they both have additional 
hydroxyl groups and double bonds.  
 
The biological activity of cyclopamine against the Hh pathway is markedly 
reduced in the acid induced isomers. However, since a major portion 
of cyclopamine does not isomerize, the remaining “regular” cyclopamine will still be able 
to inhibit the Hh pathway outside the stomach, as has been confirmed by 
others [436,465]. On the other hand, it has been reported that cyclopamine is ineffective 
regarding the Hh pathway in gastric acid [469]. As cyclopamine does not isomerize more 
than 40% or less in acid, we speculate that it is the protonation of cyclopamine in acid 
rather than isomerization that causes the drop in effect in a gastric environment. The 
importance of protonation on a drug has been previously demonstrated [499]. It was not 
determined whether the weak Hh inhibiting activity displayed by isolated isomers was 
due to the isomers themselves or due to a partial reversion to cyclopamine when in the 
aqueous environment of the cell medium. The pharmacokinetics of the isomers is 
unknown, and whether protonation or isomerization affects uptake of cyclopamine in the 
digestive tract is not clear. In addition the in vivo toxicity or side effects of the isomers 
are not known. As these isomers have remained undetected in previously reported 
analysis of cyclopamine, it may be that this is the case for other pharmaceuticals that 
have been analyzed with similar resolutions. To our knowledge, this is one of the first 
reports on sterol drugs showing a decrease in activity because of isomerization due to 
acidification. Thus we show that high-resolution analysis with shallow gradients is 
critical for detecting isomers that may be overlooked using a steep gradient. The 
awareness of pH-induced alterations of cyclopamine into nonfunctional isomers/states 
has an impact on the understanding of its pharmacokinetics and may provide a further 
basis for the rational design of bioactive analogues. For both natural cyclopamine, and 
novel analogues, it will be important to detect possible isomers with altered bioactivity, 
especially if such isomers escape detection in standard analysis. 
 
Our results with detection of a previously unreported isomer of cyclopamine 
provided an explanation to a phenomenon that was already known. Cyclopamine was less 
potent or unstable after passing though acid. The implications of this study however 
stress the importance of high-resolution analysis of drugs; especially as oral drugs are 
passing though the rough and highly acid environment in the stomach. Drug 
isomerization in itself is not a new problem, and has been highlighted before due to cases 
like the thalidomide disaster. Thalidomide was a drug used to treat nausea. In the late 
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fifties and early sixties over 10.000 children across several countries were born with 
deformities after thalidomide use by pregnant woman. One of the most common 
deformities associated with thalidomide use is Pharcomelia, where the children were born 
with “flipper” like limbs. A link between thalidomide and the birth defects was found in 
1961 [500,501], and it was later discovered that it was an optical isomer of thalidomide 
that caused the teratogenicity [502]. The safe thalidomide isomer was shown to convert to 
its teratogenic enantiomer one in the human body. Drug isomerization is thus a very 
important issue, especially considering that possible isomers may be overlooked when 
using the steep gradients commonly used in pharmacokinetic studies in drug discovery. 
 
 The compound 2-bromo-N-(4-(8-methylimidazo[1,2-a]pyridin-2-yl)phenyl)- 
benzamide (MS-0022) was identified as a potent antagonist of Hh signaling (Paper III). 
Similar to GDC-0449 and cyclopamine, MS-0022 inhibited Hh pathway activity after 
induction by various agonistic factors like Shh, oxysterols and SAG. The ability of MS-
0022 to compete with BODIPY-cyclopamine binding suggests that it acts by a similar 
mode of action as structurally related Smo antagonists, such as GDC-0449. This was 
further confirmed by the inhibition of Smo translocation to the primary cilium by MS-
0022. MS-0022 contains a core structural motif common to other Smo antagonists. 
Analysis of the core structure of MS-0022 revealed that the “phenyl-amide-phenyl” 
portion of the molecule was required for activity, and this core structure is also present in 
HhAntag [33], GDC-0449 [52], Sant-2 [53] and Compound Z [54] and other structures 
(see grey core structure, Figure 11). Although the side groups sticking out of the core 
structure in these molecules differ, their properties are similar. While MS-0022 inhibited 
Smo in the nanomolar range, it displayed an additional effect on the Hh pathway 
downstream of Smo that required a higher dose. In the micromolar range, MS-0022 led to 
a significant reduction of Gli1 mRNA and protein levels in Sufu-/- cells. This effect was 
not due to an altered or inhibited translocation of Gli1 to the nucleus, indicating that MS-
0022 did not reduce Gli1 levels by direct inhibition of Gli1. The precise cause of this 
secondary effect remains to be elucidated. As described in the introduction section of this 
thesis, several of the proteins in the Hh pathway have dual roles, and some of the 
interactions are not properly understood. It should be noted that GDC-0449 has been 
shown to block ABC class membrane transporters in addition to blocking Smo [503]; and 
although this was not investigated in this work, it could well be that this is the case for 
MS-0022 and other Smo antagonists that share similar structures.  
 
As the implications of aberrant Hh signaling are getting increasingly evident in 
many types of cancer, new pathway antagonists will be an essential part of the toolkit for 
the development of future treatments. The emerging data from clinical trials with GDC-
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0449 show both the benefits and possible pitfalls of a pure Smo antagonist; a clear tumor 
response in Hh driven tumors such as basal cell carcinoma and medulloblastoma 
[414,504,505], and the occurrence of a drug induced resistance caused by mutations in 
the Smo locus [414,504]. Our MS-0022 based research displays that Smo inhibitors are 
good candidates for Hh inhibition in cancer, but the development of resistance is a 
challenge. The mutation conferring resistance to GDC-0449 in medulloblastoma cancer 
cells was mapped to the central binding cavity in GPCR helix bundle of the Smo protein 
[414]. As several GDC-0449 related (see figure 11, compounds with a grey core 
structure) and non-related compounds appear to block Smo function, the best way to 
target Smo in cancer would likely be to exploit this diversity. By identifying Smo 
antagonists that bind to different parts of Smo, and using these in combined treatment, 
one could greatly reduce the chance of point mutations leading to treatment resistance. It 
was demonstrated by Dijkgraaf et al. that cyclopamine, Sant-1 and other Smo antagonists 
based on the GDC-0449 core structure reduced Hh signaling in tumor cells that were 
resistant to GDC-0449 [506]. Whether MS-0022 would be active against the GDC-0449 
resistant tumor cells have not been determined. Attacking a signaling pathway at two 
sites at the same time makes sense when taking the high mutation rate in cancer cells into 
account [506,507]. Thus a mutation rendering the cell resistant to one of the drugs would 
not have a much greater chance of surviving than the non-resistant cells, and the 
development two mutations at the same time is a much less likely event. The possibility 
of such a dual inhibition tactic would also be relevant to consider for other signal 
pathways that are targeted for cancer treatment. Another possible solution to blocking 
Hh/GLI1 signaling in patients with a developed resistance to a Smo antagonist would be 
to develop drugs that act on the pathway downstream of Smo [20]. A Gli inhibitor, for 
instance, could be used to target tumors harboring non-canonical activation of Gli [508] 
or mutations that cause activation of the Hh pathway downstream of Smo, in addition to 
tumors that have developed a resistanse to a Smo antagonist. However, in a recent study, 
point mutations in Smo were detected in only 7 of 135 tumors resistant to the Smo 
inhibitor NVP-LDE225 [509]. The high level of tumor-stromal interactions found in 
advanced cancers like pancreatic adenocarcinoma poses additional challenges for 
developing treatment strategies based on Hh antagonists. Such strategies would require 
that, in addition to autocrine efficacy, paracrine interactions between tumor activated 
stroma and tumor cells are disrupted [413]. Furthermore, the barrier that the stromal cells 
create around the tumor, and the lack of compound delivery to areas of low 
vascularization needs to be addressed [437].  
 
MS-0022 readily entered the body tissues after per oral administration and was 
well tolerated in vivo. In addition to blocking the growth of several tumor cell lines in 
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various assays in vitro, MS-0022 also inhibited the growth of SUIT-2 and PANC-1 
tumors in xenograft experiments. The growth inhibition appeared to be transient, and 
despite a strong growth inhibition in the early days of the treatment the growth recovered 
and eventually had the same growth pattern as the untreated tumor cells. Our in vivo 
results also lend support to the idea that the primary effect of Hh inhibition in pancreatic 
cancer treatment is due to the inhibition of Hh pathway activity in the stromal cells, 
although we also observe a mild initial reduction of Gli1 levels in tumor cells. The initial 
growth inhibition correlates with the reduction in stromal Gli1 mRNA levels after 7 days, 
while after 18 days the Gli1 mRNA levels and growth was no longer blocked by MS-
0022. Olive et al reported that treatment with another Hh inhibitor, IPI-926, that also 
displayed a transient effect in the treated tumors [437]. This study was based on mice that 
develop pancreatic tumors that resemble human pancreatic ductal adenocarcinoma due to 
a conditional expression of endogenous mutant Kras and p53 alleles in pancreatic cells 
(KPC-mice) [316,510]. Both the SUIT-2 and PANC-1 cell lines are mutant for p53 and 
Kras [511–515]. Although the transient inhibition could possibly be due both to an 
increased stromal barrier, or be due to mutations that lead to drug resistance, another 
possibility should also be considered. Hh inhibition may trigger the recruitment of other 
core signaling pathways to take over the proliferative drive in the tumors, and Smo 
inhibition could also lead to an uncoupling of Gli from Smo control, allowing other 
pathways to take over the control of Gli proteins. For instance, upregulation of PI3K 
signaling has been linked to the development of resistance against a Smo antagonist in 
cancer, but the underlying mechanism remains to be investigated [509]. 
 
Oxysterols have emerged as molecules of interest ad have ben studied within 
various fields for the last 30 years. The effect and regulation of Hh active oxysterols are 
little known, but are of great importance to investigate in order to understand this cancer 
related pathway in greater detail. As reviewed by George J. Schroepher Jr. (2000), the 
analysis of oxysterols is hampered by low physiological concentrations in comparison to 
cholesterol, autoxidation and difficulties with analytic techniques. Several separation 
techniques and analytic methods have been used and are in use today for detection of 
oxysterols. In order to detect the low amounts of oxysterol present, larger amounts of 
sample material are required. In addition the sample preparation and pre separation and 
pre-processing of the sample prior to analysis is difficult and time consuming. We report 
here (Paper IV) a sample preparation technique combined with an AFFL-SPE-LC-MS 
analysis method that allows the determination of a set of highly Hh active oxysterols 
using just one sample transfer step (from preparation tube to autosampler vial). 
Compared to established methodology, the manual sample preparation was significantly 
reduced. The total hands-on time pr. 20 lyzed cell-samples were about 10 minutes. 
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Clogging was avoided by using AFFL and excess Girard reagent did not enter the MS 
instrumentation as it did not bind to the SPE column and was flushed to waste before the 
elution of analytes. The AFFL-SPE-LC-MS methodology was validated (precision, 
sensitivity etc.) with good performance. The chromatographic resolution of the oxysterol 
isomers 22S-OHC, 24S-OHC and 25-OHC was satisfactory for our purposes, and the 
method was shown to be suitable for determination of the oxysterol analytes in various 
cell lines with a high degree of precision. The methodology was also reliable for the 
analysis of relatively small cell samples (330.000 cells), allowing us to study selected cell 
subpopulations. Thus this methodology could be used on stem cells, on cellular 
subpopulations or on other cells that are difficult to harvest in higher quantities. We have 
here focused on determination of oxysterols of known, strong potency regarding the 
Hedgehog pathway, and the methodology may be expanded in follow up studies to other 
oxysterol groups and other similar cellular lipophilic metabolites. In addition to the 
oxysterols involved in the cancer and stem cell related Hh pathway, other oxysterols are 
for instance involved in atherosclerotic plaque formation [171,516]. 24S-OHC has been 
suggested as a marker for neurodegenerative diseases like alzheimers disease and 
multiple sclerosis, as the concentration of this oxysterol is increased in the spinal fluid 
and decreased in the blood of patients suffering from these diseases [517,518]. One of the 
main reasons for the development of this methodology has been to find a way to be able 
to detect oxysterols of interest in cellular samples in the size-range normally used for 
cellular assays, as current methodology failed at this task in our hands. But we believe 
out technique could be a valuable tool in measuring oxysterols in body fluids, if they 
proov to be valid markers of disease. In addition the involvement of oxysterols in 
carcinogenesis [444], and the high levels of oxysterols we have detected in the colon 
carcinoma cell lines HCT15 and HCT116 merits further investigation to whether 
oxysterols could be a marker for cancer development or treatment progression.  
 
The use of this technique have already provided us with a couple of very 
interesting observations. The biological relevance of these observations needs to be 
validated further in follow up studies, but they have demonstrated the sensitivity and 
usefulness of the developed methodology. For instance we were able to measure the 
oxysterol content of samples from several cultured human and mouse cell lines with very 
little standard deviation between replicates. The ratio of different oxysterols across the 
analyzed cell lines varied, and was more similar between cell lines of the same species 
and cell type. In addition, two oxysterols (24S-OHC and 22S-OHC) present in the Ptch-/- 
MEF cell line were not found in the related Sufu-/- MEF cell line. It remains to be shown 
whether these levels are related to the presence/absence of Ptch-/- or if they are a result of 
differences in morphology or other cellular differences. It could also be speculated that 
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the Hh pathway in Sufu-/- cells is independent on oxysterols as the pathway is 
constitutively activated below the level of Smo. Another interesting observation is that 
inhibition of the Hh pathway by MS-0022 reduced the cellular levels of 24S-OHC by 3-
fold after 24 hours. Whether this reduction was due to enzymatic depletion or cellular 
efflux of 24S-OHC remains to be shown. As Ptch has been shown by others to pump 
cholesterol out of the cell, it is possible that Ptch could pump oxysterols in a similar 
manner. Another possibility is that the efflux of cholesterol mediated by Ptch could result 
in lower cholesterol levels and in turn lower production of oxysterols. While some reports 
claim that 24S-OHC acts as an agonist of LRX [519,520], but a newer in vivo study 
contradics this claim [521]. 24S-OHC has primarily been identified as a carrier of 
cholesterol from the brain to the liver. Unlike cholesterol, 24S-OHC can pass the 
blood/brain barrier, and about 7 mg 24S-OHC is transferred from the brain to the liver in 
a 24 hour period [522]. As oxysterols can pass cell membranes and bind lipoproteins at a 
much higher rate than cholesterol, oxysterol formation may be a mechanism utilized by 
come cells to eliminate excess cholesterol in addition or in stead of cholesterol transport 
mediated by ABC transporters and HDL [522]. In light of the discovery that GDC-0449 
blocks ABC transporters in addition to blocking Smo, the effect of MS-0022 on 24S-
OHC may not be Hh pathway related, but rather related to an effect on ABC transporters. 
The ABC transporter ABCA1, for instance,  has been shown to mediate efflux of 
oxysterols from fibroblast cells [523]. Still, a possible MS-0022 mediated blockage of 
ABC transporter efflux of cholesterol or sterols does not fit with the decreased 24S-OHC 
levels detected after MS-0022 treatment. An effect of MS-0022 on ABC transporters 
would also fail to explain how SAG would lead to an increase in 24S-OHC level in 
contrast to the reduction mediated by MS-0022. The vide variety of both synthetic and 
natural lipophilic compounds that bind and modulate Smo activity indicate that Smo 
might be a more general lipid sensory receptor. Likewise Ptch has been reported to 
modulate the levels of cholesterol [154] PI4P [163], provitamin D3 [157] and possibly 
oxysterols. Although it seems that oxysterols activate Smo directly as allosteric effectors 
[159], they may also modulate the Hh pathway through other mechanisms. Oxysterol 
binding proteins are involved in vesicle transport, late endosomes, Akt signaling and 
ERK signaling; all of which are involved in or modulate Hh signaling. It is interesting to 
note while cholesterol and 25-OHC regulates the OSBP/PP2A/PTPPBS complex and 
thereby ERK activity, PP2A has been identified as a possible Hh pathway component in 
an RNAi screen [524]. Although Nachtergaele et al. finds 20S-OHC as the primary 
oxysterol activating Smo, 22S-OHC and 25-OHC have activated the pathway similar to 
20S-OHC in our hands. In our hands 24S-OHC was more potent in activating Hh 
signaling than the other reported HH activating oxysterols. In addition we have found that 
all of these oxysterols have a synergistic effect on Hh pathway activity. It could be that 
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the specific oxysterols target different proteins, or that the binding of different oxysterols 
to the two parts of a protein dimer enhances the activity. Dimerization has been reported 
for both OSBP and Smo. The role of PI4P in Smo activation may be to recruit OSBP or 
ORP proteins to the vincinity of Smo, thus facilitating the transport of oxysterols to 
activate Smo in absence of Ptch, but this remains to bee proven.  
 
In conclusion this thesis has focused on the Hedgehog signaling pathway, an 
important developmental pathway that is abnormally activated in several forms of cancer, 
including types of cancer that are difficult to treat. The reported research has 
encompassed the natural and plant derived Hh inhibitors cyclopamine and DHV, the 
synthetic Hh inhibitor MS-0022 and cell-derived oxysterols. We have identified DHV in 
V. album, and showed that this compound is a weaker Hh antagonist than cyclopamine. 
We did, however, not find cyclopamine in the subspecies of V. album that we had acess 
to. We have identified two previously unknown isomers of cyclopamine that are formed 
when cyclopamine is in contact with acid, and showed that these isomers are an order of 
magnitude less potent antagonists of the Hh pathway that cyclopamine. These results 
confirm the weakness of cyclopamine in acidic environments. We have also characterized 
the effect of the Smo antagonist MS-0022 against cancer growth in vitro and in vivo, 
finding that although this compound reduced tumor growth in mice xenografts, the effect 
was transient. Further we have developed and effectively tested a method for detecting 
oxysterols, an important signal transducer in Hh signaling, in small cellular samples, 
making observations that merit further studies. 
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8. Appendix I. Drug discovery, target deconvolution and chemical analysis 
 
The discovery and use of natural and synthetic drugs have had a huge impact in 
medical science and practice in the last century. In short, the term “drug discovery” 
encompasses the process by which drugs are identified, tested and developed. The drugs 
in this context are molecules that modulate biological processes, often by modulating 
protein activity and function. Drug discovery is an important part in the fields of medical 
research, biotechnology and pharmacology. The use of drugs is not a new phenomenon in 
human history. Various plants and herbs have been used as natural remedies in the past 
and are still being used today. However with the development of the fields of organic 
chemistry and chemical analytics coupled with a greater understanding of genetics and 
biochemistry is has become possible to isolate the chemical compounds in a plant that has 
a biological function, as well as making new compounds that are not found in nature. The 
number of possible organic compounds that can be made with a molecular weight below 
500 Daltons is estimated to be over 1060 [525]. In comparison the earth is estimated to be 
made up of 1051 atoms. When looking for compounds that have a specific biological 
action, it is thus not feasible to synthesize and test the activity of this staggeringly high 
number of possible compounds. The strategy has instead been to make large libraries of 
compounds with as diverse chemical structures as possible, and to use a technique called 
“high-throughput screening” (HTS) to identify compounds that affect a specific 
biological process. Whereas drug discovery normally begins with HTS, it is followed by 
a Hit-to-Lead phase where the activity of possible drugs is confirmed, and the best 
candidates are chosen for further developed before animal experiments and a possible 
clinical trial. Although the scheme of drug discovery is well established it is not an easy 
process. The cost of the research and development required to produce a “new molecular 
entity” (a new approved drug that is not similar to a previously approved drug) was 
estimated to be approximately 1,8 billion USD in 2010 [526]. 
The use of HTS for identification of compounds that targets a spesific biological 
process requires the development of an assay where the activity of the biological process 
can be monitored in a large number of samples. Processing large numbers of samples and 
assays manually is very time consuming; but the use of multi-welled assay plates, 
automated robotics, control software, computer based data processing, liquid handling 
devices and sensitive detectors have speed the process up, enabling a researcher to 
conduct anything from hundreds to millions of chemical or biological tests in a relatively 
short timeframe. A wide range of detection techniques are in use, depending on the type 
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of assay, including various forms of light detection, such as luminescence measurements 
and microscopy. Computation and statistics can then be used to process the acquired data 
in order to identify compounds that affected the reaction or process used in the assay. The 
identified compounds are normally tested in additional screens and assays in order to 
verify their activity, and to identify the best candidates for further development. 
Specificity, cytotoxicity, analogging, structure-activity relationship analysis (SAR), 
deconvolution, target affinity, druglikeness, rational drug design and pharmacokinetic 
studies are important aspects of drug development and optimization. The term 
“druglikeness” describes a compound’s potential as a drug with respect to structural 
factors that influence bioavailability. There are two major approaches to HTS in drug 
discovery. The more classical approach, termed chemical genetics [527,528], has been to 
expose cells or organisms to a library of plant derived compound or synthesized 
chemicals, and to look for cellular or phenotypic changes in order to identify compounds 
that affect a biological process. As this approach yields hits that affect a system or 
process, it is challenging to identify the direct mode of action. In order to avoid this 
problem, the focus shifted to target-based drug discovery. Assays were developed where 
a specific reaction or a specific protein interaction was assayed against chemical libraries 
of compounds. The target-based drug discovery has not work as optimally as hoped 
[529], and the field has now shifted back towards more chemical genetics [527]. Several 
strategies have been developed that aim to help discover the mode of action of a potential 
drug that affects a biological process, but this can be a time consuming and difficult 
research. This determination of a compound’s mode of action is called target 
deconvolution. When a compound affects a cellular signaling pathway or a biological 
process has been identified, assays can be designed that will allow the researcher to 
distinguish at what level of a process or pathway the drug exerts its effect. But even when 
the level has been identified, target deconvolution can be a challenge. The Hh pathway is 
a good example where target deconvolution is difficult. Several of the interacting proteins 
in this signalling pathway have dual roles, and the proteins are part of several different 
protein complexes where the interactions are not fully understood. Yet, if the drug binds a 
certain protein, in theory this interaction between drug and protein should be detectable. 
One approach is the use of affinity chromatography, a technique primarily used for 
protein purification [530], in identifying cellular protein targets of small drugs [531–533]. 
The small compound of interest is tagged by introducing a chemical group called a linker. 
This linker can act to immobilize the compound by binding it to a solid material that is 
referred to as a matrix. The compound with its attached linker can then be incubated with 
a protein extract in presence of the matrix, followed by washing steps that will remove all 
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proteins that do not bind to the matrix-linked compound. After several washing steps the 
linker-matrix interaction can be disrupted to elute the bound protein for immunodetection 
[534] or MS analysis [535]. In order to use this technique, the drug of interest must 
tolerate the attachment of a linker without losing its activity. Another limitation is that a 
specific compound often can bind several types of proteins. Further steps may be required 
to distinguish which protein of a group of proteins that interact with the compound that is 
responsible for the biological activity, while removing “false positives”. Other techniques 
used in drug discovery are expression cloning technologies such as the yeast three hybrid 
system, phage display and mRNA display where protein abundance is artificially 
increased [536], protein microarray, cellular cDNA array, biochemical suppression [536] 
and anisotrophy based analysis. In order to discriminate between positive and false-
positive compound-protein interactions, the protein binding targets of a compound can be 
mapped by biological function using bioinformatics; allowing the researcher to determine 
which of the proteins is the most likely candidate to be involved in the targeted biological 
process or pathway [537]. In silico computational compound-protein interaction profiles 
[538,539] may be generated if three-dimensional protein structures are available. Various 
methods can be used to confirm a physical interaction, including surface plasmon 
resonance, resonance acoustic profiling and nuclear magnetic resonance (NMR). In order 
to verify that the compound’s effect is due to an interaction with a certain protein, it is 
possible to investigate the cellular or biological effect of altering the protein level 
directly. If the compound is a process or pathway inhibitor or agonist, an RNA 
interference knockdown of protein expression should have the same phenotype or effect. 
If the compound acts as an agonist that activates or enhances a pathway or process, 
overexpression of the identified target protein should display the same effect. 
 
The field of chemical analysis has provided several important tools that are 
important in drug discovery as well as the research fields of biochemistry and molecular 
biology in general. Tools that have been important for this thesis and that are widely used 
in drug discovery are high performance liquid chromatography (HPLC), mass 
spectrometry (MS) and NMR spectroscopy [540,541]. Chromatography is widely used to 
separate different substituents of a mixture, both in liquid and gaseous phases. In HPLC, 
a mixture is pumped with the mobile phase through a column for example containing 
particles with a stationary phase attached. For high performance (and high resolution) 
separations, the particles must be small (~2 to 5 μm). This creates a high back-pressure, 
and that is why HPLC is often called high pressure liquid chromatography. Each of the 
components in the mixture will be differentially partitioned between the stationary and 
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the mobile phase, and this will cause them to move through the system at different 
speeds. This difference is used to separate the constituents of the mixture. The chemical 
property of the stationary phase that is selected is based on what kinds of substance that is 
to be separated. The most commonly used technique today is reversed phase HPLC. The 
more hydrophobic a component is the longer it will take to move (elute) through a 
reversed phase LC system. This is opposite (reversed) of the first available LC columns, 
where more hydrophilic compounds elute later (commonly called “normal phased” liquid 
chromatography). The bioavailability of drugs depends on both hydrophilic and 
hydrophobic properties, as the drugs have to pass through body fluids and cell 
membranes. Reversed phase LC is very often used to separate drugs or drug candidates 
according to their hydrophobic properties. The time it takes for a compound to elute is 
called the retention time. After separation the different constituents of a mixture can be 
fractioned for further analysis or be monitored/analyzed in real time by coupling the LC 
system to a detector. Common detection systems are based on UV absorption 
spectrometry or MS. MS analysis however requires that the analytes are in gas phase. 
This initially limited the use of MS to gas chromatography, which is limited to analysis of 
volatile, thermostable compounds. However, the development of the electrospray 
ionization (ESI) [542] technique allowed LC to be coupled more readily to MS. In brief, 
MS analysis is based on ionization of molecules or molecular fragments before 
measuring the mass-to-charge (m/z) ratio. The MS technique has several uses, including 
aiding the determination of a compounds structure based on observations of 
fragmentation, and for identification and highly selective quantification. The ion 
abundance versus m/z is plotted in a mass spectrum. An MS instrument contains an 
ionization source, a mass analyzer and a detector. Several different ionization sources and 
mass analyzers have been developed that have different properties. The purpose of the 
ionization source is to generate ions (gaseous) that are subsequently sorted by their 
masses in the mass analyzer by utilization of electromagnetic fields. After ionization and 
sorting the m/z ratio is measured in the detector. Two key ionization methods are ESI 
[542] and matrix-assisted laser desorption/ionization (MALDI) [543] and the efforts 
related to the development of these two techniques lead to a share of the 2002 Nobel 
Prize in Chemistry.  
 
ESI is, as mentioned above, used to couple LC to MS instrumentation. In brief, 
ESI is produced when a liquid sample is passed through an electrically charged capillary. 
The polarity of the voltage applied to the capillary will result in an electrophoretic effect, 
where the eluent will have either a net positive or a net negative charge. Due to resulting 
repulsion within the eluent, it forms an aerosol spray of charged droplets (a “Coulomb 
explosion”). As the droplets pass through air or nitrogen steam the droplets shrink in size 
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due to evaporation and subsequent Coulomb explosions. Two different theories are used 
to explain the final stage of ESI, namely the event of ions entering gas phase intact [10]. 
 
 
 
According to the charge residue theory the tiny droplets formed by Coulomb 
explosions are thought to undergo complete evaporation, thus releasing the charged 
molecules. In contrast the ion evaporation theory is based on the idea that the ions are 
desorbed from the surface of the tiny droplets. The gaseous ions formed are then passed 
on to the mass analyzer part of the MS instrument. An important advantage of ESI is that 
it is a soft technique that allows e.g. non-volatile, thermolabile non covalent 
 
Figure 13. LC-MS instrumentation. A. A schematic depiction of a typical LC-MS setup. B. A figure showing 
the use of ESI as an ion source. Tiny droplets containing charged analytes are sprayed out of a capillary, and 
gas phase ions are formed due to solvent evaporation and coulomb explosions in the evaporation chamber. C. 
The quadropole ion trap mass analyzer utilizes a structure containing two endcap electrodes and a ring 
electrode. Electric fields over these electrodes are used to trap ions from the ion source and to release ions into 
the detector. D. The TOF mass analyzer separates accelerated ions based on m/z ratio as the ions drift through 
the TOF drift tube. Modified from http://www.magnet.fsu.edu/education/tutorials/tools/ionization_esi.html, 
Glish et al. 2003 [4] and El-Aneed et al. 2009 [10]. 
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biomacromolecular complexes to be ionized intact [544], offering the possibility of 
studying protein-drug complexes and other multimolecular complexes. Several kinds of 
mass analyzers with different properties are currently used in MS instrumentation, 
divided into two classes, beam analyzers and trapping analyzers. The beam analyzers are 
based on ions that leave the ionization source in a beam and pass through the analyzing 
field and on to the detector, and include mass analyzers called time-of-flight (TOF), 
sector analyzers, double focusing analyzers and quadrupole mass analyzers. The mass 
analyzers used in this thesis are the TOF [545] and quadrupole ion trap. The TOF mass 
analyser uses a simple technique where ions are separated based on their velocity. In 
theory the ions are all formed at the same time and are then allowed to accelerate through 
a fixed electric potential into a TOF drift tube that typically is 0.5-2 meters long. Each ion 
will receive the same kinetic energy in the acceleration process, and ions with a lower m/z 
ratio will move faster through the drift tube than ions with a high m/z ratio. The m/z of 
the ions is calculated from the time of ionization until the ions strike the detector. The 
quadrupole ion trap utilizes a three-dimensional electric field in order to trap ions inside 
the instrument. The ion trap is made up of two hyperbolic metal electrodes that face each 
other and that have a hyperbolic ring electrode halfway between each other. The ions are 
trapped in the space between the three electrodes by two types of electric fields; 
oscillating and non-static AC and non-oscillating and static DC fields. The ions are 
received into the trap by electrostatic gate pulses that open and close, allowing a certain 
number of ions to enter. An AC field is applied to the ring electrode in order to further 
focus the ions in the center of the trap. The trapped ions will oscillate with a certain 
frequency and are released from the trap if their trajectories become unstable. Making the 
trajectories unstable is achieved by changing the amplitude of the voltage so that the ions 
are sequentially released from low to high m/z. As the released ions collide with the 
detector into the detector mass spectrums are generated. Ions can also be ejected by 
inducing resonance conditions where the frequency of the ion is matched by a frequency 
of an additional potential applied to the end cap electrodes. The electric fields in the ion 
trap can also be used to induce fragmentation. Due to the focusing of and sequential 
release of ion “packages” the quadrupole ion trap has a very high level of sensitivity. The 
number of ions that can be allowed into the trap however is limited, as too many ions will 
reduce the overall performance of the trap due to electric field distortions.  
NMR is a research technique that exploits the ability of magnetic atomic isotopes 
to (in a magnetic field) absorb and re-emit electromagnetic radiation in order to 
determine the physical, chemical and biological properties of single atoms or molecules. 
NMR is for instance utilized in medical imaging techniques of e.g. tissue (magnetic 
resonance imaging (MRI)), but in drug discovery NMR analysis provides information 
about the chemical structure, dynamics, reaction state and chemical environment of 
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molecules. NMR measurement is made possible due to atomic isotopes such as 1H and 
13C that possess a magnetic moment due to a property called nuclear spin. Each nucleus 
in a molecule will be encompassed by a local magnetic field induced by the currents of 
electrons in the molecular orbitals and atoms surrounding it. The electron distribution 
around a nucleus depends on the binding partners, bond lengths and bond angles, 
resulting in differences in the local magnetic field around each nucleus. Hence, the NMR 
signal of an atom depends on the properties of its neighbors. This information can be 
used to determine the structure of the molecule. The magnetic properties correspond to 
specific resonance frequencies in a magnetic field, referred to as the chemical shift. The 
chemical shit of a certain nucleus in NMR spectroscopy is given as the resonant 
frequency relative to a standard. By measuring the chemical shifts in a sample molecule, 
it is possible to determine structural information about a molecule. For instance, the 
chemical shift of a proton neighboring an electronegative atom will be ~ 4 ppm, but 
closer to 0 when neighboring an electropositive group. 
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Abstract
Background: Hedgehog (Hh) signaling is over-activated in several solid tumors where it plays a central role in cell growth,
stroma recruitment and tumor progression. In the Hh signaling pathway, the Smoothened (SMO) receptor comprises a
primary drug target with experimental small molecule SMO antagonists currently being evaluated in clinical trials.
Principal Findings: Using Shh-Light II (Shh-L2) and alkaline phosphatase (AP) based screening formats on a ‘‘focused
diversity’’ library we identified a novel small molecule inhibitor of the Hh pathway, MS-0022 (2-bromo-N-(4-(8-
methylimidazo[1,2-a]pyridin-2-yl)phenyl)benzamide). MS-0022 showed effective Hh signaling pathway inhibition at the
level of SMO in the low nM range, and Hh pathway inhibition downstream of Suppressor of fused (SUFU) in the low mM
range. MS-0022 reduced growth in the tumor cell lines PANC-1, SUIT-2, PC-3 and FEMX in vitro. MS-0022 treatment led to a
transient delay of tumor growth that correlated with a reduction of stromal Gli1 levels in SUIT-2 xenografts in vivo.
Significance: We document the in vitro and in vivo efficacy and bioavailability of a novel small molecule SMO antagonist,
MS-0022. Although MS-0022 primarily interferes with Hh signaling at the level of SMO, it also has a downstream inhibitory
effect and leads to a stronger reduction of growth in several tumor cell lines when compared to related SMO antagonists.
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Introduction
The Hedgehog (Hh) signaling pathway is one of the key
regulators in vertebrate development and is highly conserved
among species from fruit flies to humans [1–4]. It is also one of the
key pathways that regulate stem cells in the adult body [5].
Aberrant Hh signaling has been associated with a number of
human tumors where the pathway has been implicated in tumor
growth, malignancy, metastasis, and cancer stem cells [6–9]. Thus,
the Hh pathway has become a focus for drug discovery and
development [10–15].
The Hh pathway is unusual by several means, and central
aspects of its functioning remain to be explored. The morphogens
IHH, DHH and SHH interact with the 12-pass transmembrane
receptor Patched (PTCH). PTCH inhibits the physically separate
7-pass transmembrane receptor Smoothened (SMO) by gating the
movement of SMO into cilia. Evidence suggests, that upon Hh
binding, PTCH leaves the shaft of the primary cilium which allows
SMO to enter from its inactive endosomal state into cilia [16–18].
Furthermore, it has been proposed that SMO exists in an inactive
and active state [19,20] that may be regulated through a
hypothesized sterol-like small molecule [4,19,21]. SMO migration
into the primary cilium is followed by the inactivation of
Suppressor of fused (SUFU) [22]. Current data suggest that
SUFU, being a part of a multiprotein complex that also includes b-
arrestin, KIF3a and IFT88, impedes the nuclear localization of
GLI proteins [16,17,22]. In addition it may act as a nuclear co-
repressor [23]. SUFU is ubiquitinated upon the activation of Hh
signaling which initiates its degradation in the proteasomes [24]
leading to the release of GLI2/3 into the nucleus where they
regulate transcription of downstream target genes including the
activating transcription factor GLI1. Although GLI1 presence in
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the nucleus is primarily a consequence of active Hh signaling, it
can be attenuated by other signaling pathways [25].
There are several key mechanisms in tumorigenesis that may
involve Hh/GLI signaling [11,13]; first, inactivating mutations in
the negative regulators PTCH or SUFU, or activating mutations
in the positive regulator SMO cause pathway activation in a cell-
autonomous and Hh ligand independent manner [5,26–28];
secondly, ligand-dependent autocrine mechanisms in which
cancer cells both secrete and respond to Hh ligands causing cell-
autonomous pathway activation [29,30]; thirdly, paracrine
mechanisms in which stromal cells are induced by Hh producing
cancer cells [31–34]. Both autocrine and paracrine effects can lead
to heterogeneity with respect to Hh pathway activity within a
tumor [35]. Several SMO antagonists have been developed and
early data show clinical efficacy in selected tumors [36]. However,
there has been some debate whether the in vivo growth inhibition
observed for Hh antagonists is due to inhibition of autocrine or
paracrine Hh signaling. Several recent studies suggest that the
primary role of Hh inhibition in Hh secreting tumors may be due
to the inhibition of paracrine signaling involving tumor-stroma
interactions [33,37–41]. In particular, tumor derived SHH has
been shown to promote desmoplasia in pancreatic cancer [42],
where the induced stroma in combination with poor vasculariza-
tion may act as a barrier that is linked to a poor response to
chemotherapy [40,41].
Following the identification of cyclopamine as a natural SMO
inhibitor [43–45], several Hh pathway antagonists have been
reported that either act at the level of SMO [46], GLI1 [47], or
other parts of the pathway [10,13,36]. Among these inhibitors,
some have been progressed to clinical trials. One of these, GDC-
0449 [15,34,48], is currently in several phase I and phase II
clinical trials for various types of cancers, including pancreatic
cancer (trial ID: NCT01064622 and NCT00878163). Also, the
cyclopamine derivative IPI-926 [14] has been through a phase I
clinical trial in patients with non-disclosed advanced and/or
metastatic solid tumors, and is currently in a phase Ib/II clinical
trial in patients with untreated metastatic pancreatic cancer (trial
ID: NCT01130142).
Here, we describe the identification and evaluation of a novel
small molecule SMO antagonist, MS-0022. MS-0022 displays a
differential efficacy on various solid tumors in vitro and on PANC-1
and SUIT-2 xenografts in vivo. The reported findings are a further
confirmation of the potential of small molecule Hh antagonists as
anticancer agents.
Results
Identification of the novel Hh antagonist MS-0022
To identify novel antagonists to Hh signaling, a focused diversity
library of 12,000 compounds (10 mM) was screened using
C3H10T1/2 cells induced by recombinant human SHH and
employing an alkaline phosphatase (AP) readout in high throughput
format [49], followed by a verification step using Shh-L2 cells. MS-
0022 (2-bromo-N-(4-(8-methylimidazo[1,2-a]pyridin-2-yl)phenyl)-
benzamide), was identified as a potent Hh pathway antagonist with
an IC50 of 100 nM in Shh-L2 cells. The structure of MS-0022 was
confirmed by 1H and 13C NMR (Table S1 and Figure S1). In order
to explore the parts of the core structure required for activity in MS-
0022, a small scale broad structural analysis was performed based
on activity inhibition in Shh-L2 cells. As shown in Table 1, a
deletion of the 2-bromophenyl or the Imidazo[1,2-a]pyridine
moiety of MS-0022 led to a substantial loss of activity (for the
structure backbone see Figure 1A). The activity was partially
retained when replacing the Imidazo[1,2-a]pyridine system with a
napthlene-2-ylcarbamoyl system (MS-0018) or a 6-morpholinopyr-
idazin-3-yl system (MS-0015). A further focused structural analysis
of a limited number of MS-0022 analogs is shown in Table 2 (for the
base structure see Figure 1B).
Changing R2 from a hydrogen to a methyl group reduced
activity 6-fold (MS-0030). Incorporation of a nitrogen atom in
position Y reduced activity 23-fold (MS-0031). Substitution of R3
with a 2-fluorophenyl group reduced activity 1.6-fold (MS-0032).
Interestingly, if R1 was replaced with a hydrogen and R3 with 4-
methoxyphenyl, the activity dropped 1.8-fold (MS-0033). If R1 of
MS-0033 was replaced with a nitrogen atom in the ring (MS-0035),
the activity dropped an additional 8-fold. In general, a nitrogen
atom in the 8-position of the imidazo[1,2-a]pyridine ring system
caused a significant reduction in activity. Furthermore, a nitrogen
atom placed in position Y impacted the activity negatively.
A dose response curve of MS-0022 in Shh activated Shh-L2
cells, is shown in Figure 1C, using cyclopamine and GDC-0449 as
a comparison. MS-0022 exhibited an IC50 of 100 nM, while
cyclopamine exhibited an IC50 of 210 nM and GDC-0449 an
IC50 of 30 nM.
To ascertain that the compounds interacted at the level of
SMO, the most potent compounds, MS-0022, MS-0032 and MS-
0033 were shown to compete with BODIPY-cyclopamine with
IC50
’s of 259, 93 and 287 nM respectively (Table 2). Thus, MS-
0022 and analogs of MS-0022, as well as GDC-0449, inhibit Hh
Table 1. Activity of MS-0022 and deletion/substitution analogs (See structure in figure 1A).
ID R1 R2 R3 MW IC50 (Shh-L2, nM)
MS-0022 8-methylimidazo[1,2-a]pyridine – 2-bromophenyl 406.3 100
MS-0011 8-methylimidazo[1,2-a]pyridine – Methyl 265.3 .20,000
MS-0012 8-methylimidazo[1,2-a]pyridine – 2-propyl 293.4 .20,000
MS-0013 – O-Amide 2-bromophenyl 319.2 .20,000
MS-0014 Propyl – 2-bromophenyl 318.2 10,000
MS-0015 6-morpholinopyridazin-3-yl – 2-bromophenyl 439.3 800
MS-0016 (6-phenylpyrimidin-4-yl)amino – 2-bromophenyl 445.3 2000
MS-0017 naphthalen-2-ylcarbamoyl – 2-bromophenyl 445.3 280
MS-0018 2-benzylidenehydrazinecarbonyl – 2-bromophenyl 442.3 5000
Table depicting molecular weight and bological activity (nM IC50) of deletion or substitution analogs of MS-0022 as measured by pathway inhibition in Shh induced
Shh-L2 cells.
doi:10.1371/journal.pone.0019904.t001
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signaling at the level of SMO. MS-0022 inhibited SMO with
similar affinity as cyclopamine.
MS-0022 blocks Hh signaling at the level of SMO, but has
additional activity downstream of SUFU
MS-0022 was shown to compete with BODIPY-cyclopamine,
and the observed effect on C3H10T1/2 cells and Shh-L2 cells
suggested that MS-0022 blocks Hh signaling at the level of SMO.
However, to further verify the function of MS-0022 as a SMO
blocker, the activity of MS-0022 was evaluated in experiments that
explore the various modes of Hh signaling induction in mouse cell
lines. Upstream of Gli, Hh signaling can be induced by the Hh
morphogens; by functional loss of Ptch, as present in the
constitutively active Ptch2/2 mouse embryonic fibroblast
(MEF) cell line; by a combination of the activating oxysterols
hydroxycholesterol 20-alpha and hydroxycholesterol 22S (Ac-
tOXS) and by the SMO agonist SAG and by Sufu inactivation, as
present in Sufu2/2 MEFs. As seen in Figure 1D, MS-0022
blocked Hh pathway induction in Shh, SAG and ActOXS induced
Shh-L2 cells similarly to GDC-0449 and cyclopamine. MS-0022
also reduced Gli1 mRNA expression in Ptch2/2 MEFs, similar
to GDC-0449 and cyclopamine (Figure 1E). Cyclopamine blocks
Smo function within primary cilia without blocking its transloca-
tion to the cilia. In contrast, MS-0022 effectively blocked ciliary
accumulation of Smo (Figure 1F-H), indicating an effect on the
level of Smo similar to GDC-0449, but divergent from
cyclopamine. Primary cilia in reporter cells were identified using
an antibody against the ciliary maker acetylated tubulin.
Acetylation of tubulin is found in stabilized microtubular
structures like cilia and mitotic spindles, and has effectively been
used as a marker for cilia in various studies [50,51].
As expected for a SMO antagonist, cyclopamine and GDC-
0449 exhibited little inhibitory effect on Hh signaling downstream
of Smo in Sufu2/2MEFs. In contrast, MS-0022 reduced relative
Gli1 mRNA levels Sufu2/2 MEFs by 50% at a dose of 10 mM
(Figure 1I). Further downstream, at the level of Gli1 or Gli2, Hh
pathway inhibitory effect by MS-0022 was not detected as
indicated by the lack of inhibition of a forced expression of either
of the two transcription factors with 10 mMofMS-0022 (Figure 1J).
MS-0022 was able to show partial inhibition (Figure 1J) of Gli1 or
Gli2, only when the Hh signaling pathway was further activated by
Shh. In order to further elucidate the activity of MS-0022, Sufu2/
2 MEF cells that have been treated with MS-0022, cyclopamine
or GDC-0449 were stained with an antibody recognizing Gli1.
The intensity of Gli1 staining in the nucleus and the cytoplasm was
measured, and neither of the treatments resulted in a shift in the
ratio of Gli1 in the nucleus versus the cytoplasm (Figure 1K). Thus
the reduction of Gli1 mRNA levels in the Sufu2/2 MEF cells by
MS-0022 was not a consequence of Gli1 relocation in the cell.
However, while the treatment with 20 mM MS-0022 did not alter
the ratio of nuclear versus cytoplasmic Gli1, the total level of Gli1
in the cells was reduced (Figure 1 L–M), correlating well with the
Table 2. Activity analysis of MS-0022 chemotype (See structure in figure 1B).
ID R1 R2 R3 X Y MW
IC50 (Shh-L2,
nM)
IC50 (nM, BODIPY-
cyclopamine inhib.) cLogP PSA
MS-0022 CH3 H 2-bromophenyl C C 406.3 100 259 5.44 46.4
MS-0030 CH3 CH3 2-bromophenyl C C 420.3 630 – 5.86 46.4
MS-0031 CH3 H 2-bromophenyl C N 407.3 2300 – 3.88 59.29
MS-0032 CH3 H 2-fluorophenyl C C 345.4 161 93 4.39 46.2
MS-0033 H H 4-methoxyphenyl C C 343.4 181 287 4.24 55.63
MS-0034 – H 2-methoxyphenyl N C 344.4 .10,000 – 3.21 68.5
MS-0035 – H 4-methoxyphenyl N C 344.4 877 – 3.1 68.52
MS-0036 – H 3,5-dimethylphenyl N C 342.4 3,700 – 4.06 59.29
MS-0037 – H 3-chlorophenyl N C 348.8 1,870 – 3.87 59.29
MS-0038 – H 2-trifluoromethylphenyl N C 382.3 1,150 – 2.98 59.3
Biological activity of side group analogues of MS-0022 measured by pathway inhibition in Shh induced Shh-L2 cells and by BODIPY-cyclopamine competition, including
cLogP (computed LogP, octanol/water partition coefficient) and polar surface area (PSA).
doi:10.1371/journal.pone.0019904.t002
Figure 1. Identification and activity of MS-0022. A) Structure for Table 1. B) Structure for Table 2. C) Dose response curves of indicated
compounds in Shh activated Shh-L2 cells after 48 hours treatment (n = 8). D) Shh-L2 cells activated with Shh, 200 nM SAG and ActOxs (5 mM+5 mM)
treated with indicated compounds at 5 mM for 48 hours. Graph displays fold Hh reporter activity with standard deviation (SD) (n = 3). The basal
activity (DMSO) was set as = 1. E) Normalized (GADPH) Gli1 mRNA expression in Ptch2/2MEF after 48 hours of treatment with indicated compounds
at 5 mM. Graph displays fold expression compared to DMSO control, with SD (n = 3). F–H) Immunostaining of Ptch 2/2 MEF cells treated with MS-
0022 or DMSO control for 24 hours (anti-smoothened (Smo) in green, anti acetylated Tubulin (aTub) in red, DAPI in blue). Treated and control culture
slides (n = 3) were stained and 3 regions on each slide was imaged and analyzed. F) Graph displaying the ratio of Smo positive cilia versus total
number of cilia in stained cells by eye count, with SD. G) Graph displaying the ratio of mean ciliary intensity of Smo staining versus aTub as quantified
using ImageJ software, with SD. I) Dose response curve of MS-0022, GDC-0449 and cyclopamine by normalized (GAPDH) Gli1 mRNA expression in
Sufu 2/2 MEF after 72 hours treatment (n = 3). J) NIH3T3 cells cotransfected with GliBS-Luc in combination with pBluescript (pBS), FL-GLI1-HA or
Gli2-GFP, were treated with DMSO, 50% Shh conditioned medium, 10 mM MS-0022 and a combination of Shh and 10 mM MS-0022 for 48 hours.
Graph displays relative Hh pathway activity (reporter firefly luciferase normalized for renilla transfection control), with SD (n = 3). K–M)
Immunostaining of Sufu2/2 MEF cells treated with DMSO control, MS-0022 (5, 10 and 20 mM), cyclopamine (20 mM) and GDC-0449 (20 mM) for
48 hours (n = 3). K) Graph displaying ratio of nuclear Gli1 staining intensity versus cytoplasmic Gli1 staining intensity, with SD. L) Graph displaying
sum of nuclear and cytoplasmic Gli1 staining intensity in treated cells, with SD.
doi:10.1371/journal.pone.0019904.g001
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reduction in Gli1 mRNA. At the same dose GDC-0449 also
reduced Gli1 levels in the cells, but to a lesser extent than MS-
0022 (Figure 1L), while cyclopamine had no significant effect.
We conclude that MS-0022 acts at the level of SMO blocking its
ciliary transport in the nanomolar range. An additional inhibitory
effect of MS-0022 on Hh signaling downstream of Sufu that
required a dose in the 10–20 micro molar range is linked to a
reduction of Gli1 protein levels.
MS-0022 blocks tumor growth in pancreatic
adenocarcinoma, prostate carcinoma and melanoma cell
lines in vitro
To test in vitro efficacy of MS-0022, we profiled the presence of
central components of the Hh signaling pathway in the pancreas
adenocarcinoma cell lines PANC-1 and SUIT-2, the prostate
cancer cell line PC-3, and the melanoma cell line FEMX by real
time PCR (Table 3). Although all cell lines expressed detectable
levels of GLI1 mRNA, the level of expression varied, as did other
components of the Hh signaling pathway. However, the clear
presence of the direct Hh downstream marker PTCH1 in all cell
lines, indicated Hh/GLI1 pathway activity.
To determine if GLI1 mRNA levels in the tumor cells could be
reduced byMS-0022, real time PCR was carried out on cells treated
with different doses of MS-0022, cyclopamine and GDC-0449 for
48 hrs (Figure 2A). In parallel, growth inhibition was measured by
MTS (Figure 2B). For the PANC-1 cell line, growth inhibition and
reduction of GLI1 mRNA levels upon treatment, correlated well at
10 mM for all three compounds. At 5 mM, however, MS-0022 and
GDC-0449 reduced growth without reducing GLI1 mRNA levels.
In the SUIT-2 cell line, MS-0022, cyclopamine and GDC-0449 all
reduced GLI1 mRNA levels, but only MS-0022 reduced growth.
For the PC-3 cell line, bothMS-0022 and GDC-0449 reduced GLI1
mRNA levels, although growth was only reduced by MS-0022. For
the FEMX cell line, the growth and GLI1 mRNA levels correlated
well at 10 mM, but not at 5 mM. In conclusion, using the SMO
antagonists GDC-0449 and cyclopamine, no correlation between
growth inhibition and reduction of GLI1 mRNA levels could be
detected in the four tumor cell lines PANC-1, SUIT-2, PC-3 and
FEMX. However, a correlation between growth inhibition and
GLI1 mRNA levels were apparent at a dose of 10 mM MS-0022
across all four tumor cell lines. The data set is consistent with an
additional Hh pathway inhibitory effect of MS-0022 downstream of
SMO/SUFU that requires relative higher doses of the compound as
compared to direct SMO inhibition. As seen in Figure 2B, both
CDG-0449 and cyclopamine did not lead to more than 30% growth
reduction in the tested cell lines PANC-1, SUIT-2, PC-3 and FEMX
during a 4 day exposure to 10 mM compound in a MTS assay. In
contrast, at the same dose, MS-0022 reduced growth from 40%–
70% in the same cell lines (Figure 2B). An immortalized,
non-tumorigenic hepatocyte cell line, THLE-2, was included as a
control, and the THLE-2 cells responded with a 25%–30% growth
reduction to 10 mM compound exposure possibly indicating a weak
Hh dependency in this control cell line (Figure 2B).
To address growth inhibition in a model relevant to xenograft
studies, PANC-1 and SUIT-2 cells were seeded in a soft agar
colony forming assay. A dose response curve was generated for
MS-0022, while using GDC-0229 and cyclopamine as controls.
For both cell lines, treatment with MS-0022 led to a reduction in
large (Figure 2C–D, and G) and medium sized colonies in a dose
dependant manner (Figure 2E–F, and G). Also upon MS-0022
treatment, an increase in the number of small colonies was
observed, indicating that the reduced growth of the small and
medium sized colonies is linked to decreased proliferation rather
than apoptosis. The cyclopamine control was excluded from the
dataset due to problems with crystallization of cyclopamine in the
soft agar.
Long term growth assays with 2–3 serial passages (5–7 days per
passage) further confirmed the efficacy of MS-0022 on the tested
PANC-1, SUIT-2, PC-3 and control THLE-2 cell lines (Figure 2H).
In the presence of 5 mM MS-0022, there was an initial growth
reduction in the first passage of the control THLE-2 cells, but by the
second passage the growth was not affected by the treatment. In
contrast, the growth was reduced by 80% in PANC-1 cells and PC-3
cells after passage 2. Serial passage growth reduction was not
significant for passage 2 and 3 in the SUIT-2 cells.
Pathway specificity
To address possible effects of MS-0022 on other central
signaling pathways, we analyzed whether MS-0022 affected Wnt
and TNF-a signaling using firefly luciferase reporter assays. As
seen in Figure 3A, MS-0022 did not significantly block L1 medium
induced Wnt signaling in HEK293 cells, nor did it block TNF-a
induced NfkB signaling in NIH3T3 cells at 10 mM and 20 mM
(Figure 3B). Instead, MS-0022 led to a slight increase of NFkB
signaling (Figure 3B). In addition, MS-0022 was tested at 10 mM
in a Millipore diversity panel comprised of 58 kinases. MS-0022
did not significantly inhibit the activity of any of the tested kinases
(Table 4).
Efficacy and bioavailability of MS-0022 in an in vivo
pancreatic adenocarcinoma xenograft model
In preparation for in vivo xenografts, the bioavailability of MS-
0022 in mouse plasma was evaluated. The maximum concentra-
tion (Cmax) of the compound in plasma was 934 ng/mL upon a
5 mg/kg IV injection. For a 5 mg/kg IP injection, it was 378 ng/
mL and after 5 mg/kg PO administration, it was 912 ng/mL
(Figure 3D–F and Table 5). Per oral bioavailability was calculated
to be 98%. The half-life (T1/2) after MS-0022 administration was
between 55 and 60 minutes, indicating that MS-0022 has a
moderate stability in plasma. Compound concentration in mouse
liver tissue 2 hours after IP administration was 244 ng/g. Thus,
MS-0022 readily enters tissue from the plasma. Overall, the
compound exhibited good exposure and moderate stability in
plasma.
Next the in vivo tolerability of MS-0022 was examined. No
statistically significant alterations in body weight were observed in
animals treated with daily IP injections of 200 mg/kg of MS-0022
for 5 days (Figure 3G), indicating that the compound was well
tolerated. Mice did not show any outward signs of toxicity or other
side effects (weight loss, fur ruffling, hunched posture). Even
though there were no outward signs of side effects or toxicity, we
analyzed the AST/ALT levels as a measure of liver toxicity in
xenografted animals that had been treated with MS-0022 for a
Table 3. Expression profile, Tumor cell lines.
PTCH1 SMO GLI1 GLI2 GLI3 SHH HIP SUFU
PANC-1 +++ + +++ +++ + +++ +/2 +++
SUIT-2 ++ ++ ++ ++ nt +++ nt nt
PC-3 ++ ++ ++ + + +++ + +
FEMX ++ + + + 2 2 2 +
Expression analysis of tumor cell lines according to the PCR cycle where
amplification was detected, starting with 1 mg mRNA (+++=20–25, ++= 25–30,
+= 30–35, 2=.35 and nt = not tested).
doi:10.1371/journal.pone.0019904.t003
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longer time period than 5 days. As the liver normally acts as the
primary site of drug metabolism, AST/ALT serum levels is an
easily obtainable measure of toxic side effects. As seen in
Figure 3C, AST/ALT levels remained greater than 1 in mice
treated with 50 mg/kg of MS-0022 after a 30 days injection
scheme (5 day injection, 2 day pause), suggesting that at this dose
MS-0022 was well tolerated without apparent toxic effects in the
liver in comparison to the control treated mice.
In-vivo efficacy of MS-0022 was tested against two pancreatic
adenocarcinoma cell lines PANC-1 and SUIT-2. For PANC-1,
subcutaneous tumors were established in CB17/SCID mice
(n = 6). Mice were randomized and dosed with control solvent
(water with 1% Tween 80) or MS-0022 (QD, IP at 50 mg/kg) in a
5 day injection/2 day pause scheme. Tumor volumes were
evaluated throughout the treatment by measuring two perpendic-
ular diameters with calipers, and by calculating tumor volume
(mm3) using the formula V = a6b26,Pi./6. At the end of the
treatment there was a 38% reduction in tumor volume and a 33%
reduction in tumor weight compared to tumors in control solvent
treated littermates (Figure 3H–I). The growth curve (Figure 3H),
shows that the tumors in both control and treated groups
eventually reached a similar growth pattern, and the growth
inhibition by MS-0022 appeared to be transient. At the endpoint
of the experiment, no statistically relevant difference in human
(tumor) or mouse (stroma) Ptch1 or Gli1 mRNA levels could be
identified in the extracted tumor mRNA (P.0.05) (Figure 3J).
Compared to PANC-1, SUIT-2 cells displayed a stronger
responsiveness to MS-0022 in vitro, both in the reduction of
GLI1 expression and in growth (MTS assay). Therefore, the
effect of MS-0022 was also tested in vivo using SUIT-2 pancreas
adenocarcinoma cells, and subcutaneous tumors were estab-
lished in CB17/SCID mice (n = 11). Mice were randomized
and dosed daily with solvent or 50 mg/kg MS-0022 via PO
administration. The MS-0022 treatment did not result in any
outwards signs of toxicity in the mice, and animal weight
(Figure 4C) was unaffected by the treatment when compared to
the animals that received control solvent. After 7 days, 3 mice
from each treatment group were sacrificed and the tumors
were harvested for analysis, while the remaining animals (n = 8)
were sacrificed after 18 days of treatment, due to tumor
burden. In general, the SUIT-2 tumors showed a more
aggressive growth in comparison to the PANC-1 tumors. At
the endpoint of the experiment, a 27% reduction in tumor
volume and a 36% reduction in tumor weight were measured
in treated animals compared to the control group (Figure 4A–
B). Similar to PANC-1 xenografts (Figure 3D), a transient delay
of growth was observed during the first days of treatment,
followed by a recovery of growth with growth rates similar to
untreated tumors. As in PANC-1 xenografts, no statistical
relevant reduction of human or mouse Gli1, or Ptch1 mRNA
levels was detectable at the endpoint of the experiment
(Figure 4E). However, when samples from the SUIT-2
xenografts were analyzed after 7 days of treatment only,
mouse (stromal) Gli1 mRNA in the tumors was reduced
significantly (P,0.001), while both human and mouse PTCH
and human GLI1 remained unaltered (P.0.05) (Figure 4D).
There was no detectable difference in animal weight between
the control and MS-0022 treated animals (Figure 4C). As
inhibition of SMO has been linked to an increase in
vascularization in poorly vascularized tumors [41], we inves-
tigated the vascularization of the tumor tissue upon MS-0022
treatment. Samples from the harvested tumors were cryosec-
tioned, fixed and stained for the presence of the endothelial cell
marker (CD31), as a marker for microvessles in tumor tissue.
Large variations in SUIT-2 tumor shape including the
occurrence of necrotic cavities, led to substantial variations in
the vascularization of the tumors in all samples derived after 7
or 18 days of treatment and in control samples. Due to
substantial variability, no apparent difference between the
vascularization of samples derived from treated and untreated
animals was detectable. Irrespective of MS-0022 treatment,
CD31 staining revealed high vascularization at the tumor edge,
while vascularization in the center of the tumor was generally
low (Figure 4F).
Discussion
MS-0022 was identified as a potent antagonist of Hh signaling
that blocks the translocation of SMO to the cilia displaying a
transient in vivo antagonistic effect in a pancreatic adenocarcinoma
xenograft model.
MS-0022 contains a core structural motif common to other
SMO antagonists. Analysis of the core structure of MS-0022
revealed that the ‘‘phenyl-amide-phenyl’’ (Figure 1A, where R3 =
phenyl) portion of the molecule was also present in HhAntag [33],
GDC-0449 [52], Sant-2 [53] and Compound Z [54]. Deleting the
2-bromobenzene moiety of MS-0022 resulted in a total loss of
activity, confirming the importance of the identified core structure
for the activity of this class of molecules. Interestingly, although the
‘‘phenyl-amide-phenyl’’ core is identical in all of these molecules,
there are also important differences in the structures. HhAntag,
Sant-2 and Compound Z are closer to each other in structure than
MS-0022 and GDC-0449, as they share a 1H-benzoimidazo
structure coupled in the 3 position to the 4-chloro-N-phenyl.
Interestingly, when the imidazo[1,2-a]pyridine of MS-0022 was
deleted, activity was reduced. However, when it was substituted
with groups that contain nitrogen in ortho position to the N-
phenyl, partial activity was retained. Similar to GDC-0449 and
cyclopamine, MS-0022 inhibited the Hh pathway activity after
induction by various agonistic factors like Shh, oxysterols and
SAG. The ability of MS-0022 to compete with BOPIDY-
cyclopamine binding suggests that it acts by a similar mode of
action as structurally related SMO antagonists, such as GDC-
0449. This was further confirmed by the inhibition of SMO
translocation to the primary cilium by MS-0022. While MS-0022
inhibited SMO in the nanomolar range, it displayed an additional
effect on the Hh pathway downstream of SMO that required a
higher dose. In the micromolar range, MS-0022 led to a significant
Figure 2. In vitro activity in tumor cell lines and a control cell line. A) Graphs displaying dose response curves of normalized (GAPDH) Gli1
mRNA expression in indicated tumor cell lines after 48 hour treatment of MS-0022, cyclopamine and GDC-0449. Graphs include standard deviation
(n = 3). B) Graphs displaying 4 day dose response curves of cell growth as a % growth of DMSO control (MTS) for PANC-1, SUIT-2, PC-3, FEMX and
THLE-2 cells treated with MS-0022, GDC-0449 and cyclopamine at the indicated dose, with SD (n = 8) C-G) Soft agar colony formation assay of PANC-1
(21 days) and SUIT-2 (14 days) cells treated with DMSO or MS-0022 and GDC-0449 at the indicated doses (n = 3). Each well was imaged and colonies
were counted by eye according to size. Graphs displaying the colony count of larger colonies (0.5–1 mm) are shown in C) for PANC-1 and D) for SUIT-
2, with SD. Graphs displaying the colony count of medium (0.2–0.5 mm) and small (,0.2 mm) colonies are shown in E) for PANC-1 and F) for SUIT-2,
with SD. H) Passage growth assays with PANC-1, SUIT-2, PC-3 and THLE-2 cell lines treated with DMSO control or 5 mM MS-0022 for 2–3 passages of
5–7 days, displayed as % growth of DMSO control, with SD (n = 3).
doi:10.1371/journal.pone.0019904.g002
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Figure 3. In vitro MS-0022 pathway selectivity, in vivo tolerance and distribution, and activity in a PANC-1 xenograft model. A)
HEK293 cells cotransfected with SuperTop-luc (ST-Luc) and pRL-TK, were treated with control medium and L1 medium +/2 10 and 20 mM MS-0022 for
24 hours. Graph displays fold reporter activity with standard deviation (n=3). B) NIH3T3 cells cotransfected with NFkB-luc and pRL-TK, treated with control
medium and 10 ng/mL TNF-a +/2 10 and 20 mM NFkB inhibitor Bay11-7082 or 10 and 20 mMMS-0022 for 24 hours. Graph displays fold reporter activity
with SD (n=3). C) Graph depicting average AST/ALT ratio frommouse blood at end of animal treatment in the PANC-1 xenograft. D–F) Blood distribution
curves after IV, IP and PO administration of 5 mg/kg MS-0022 in mice. Graphs display mean dose (ng/mL by time) +/2 SD. G) Body weight change in
animals treated with 200 mg/kg MS-0022 over 5 days, with SD (n=5). H–J) Analysis of subcutaneous PANC-1 tumors in mice treated with solvent control
or 50 mg/kg MS-0022 for 21 days (n= 6) by IP administration. H) Growth curves of PANC-1 tumors in mice after 30 days of treatment, showing average
tumor volume (mm3) with standard error of the mean (SEM). I) Graph displaying average PANC-1 tumor weight at end of treatment, with SD. J) Graph
displays normalized (GUSB) fold expression of mouse and human Gli1 and Ptch in treated tumors, with SD (n=3). * = P value,0.05. (n.s. = P value.0.05).
doi:10.1371/journal.pone.0019904.g003
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reduction of Gli1 mRNA and protein levels in Sufu2/2 cells.
This effect was not due to an altered or inhibited translocation of
Gli1 to the nucleus, indicating that MS-0022 did not reduce Gli1
levels by direct inhibition of Gli1. The precise cause of this
secondary effect remains to be elucidated.
As the implications of aberrant Hh signaling are getting
increasingly evident in several cancers, pathway antagonists will
be an essential toolkit for development of future treatments. The
emerging data from clinical trials with GDC-0449 show both the
benefits and possible pitfalls of a pure SMO antagonist; a clear
tumor response in Hh driven tumors such as basal cell carcinoma
and medulloblastoma [34,55,56], and the occurrence of a drug
induced resistance caused by mutations in the Smo locus [34,55].
A possible solution to block Hh/GLI1signalling despite activation
mutations in the Smo locus would be to develop drugs that act on
the pathway downstream of SMO [47]. A GLI inhibitor would
also address non-canonical activation of GLI [57].
The high level of tumor-stroma interactions found in advanced
cancers like pancreatic adenocarcinoma poses additional chal-
lenges for developing treatment strategies based on Hh
antagonists. Such strategies would require that, in addition to
autocrine efficacy, paracrine interactions between tumor activat-
ed stroma and tumor cells are disrupted [33]. Furthermore, the
barrier that the stromal cells create around the tumor, and the
lack of compound delivery to areas of low vascularization need to
be addressed [41].
The physiochemical properties of MS-0022 (MW =406.3;
clogP: 5.44; PSA: 46.4 (Table 2)), its excellent per oral
bioavailability, and the initial evidence that it is well tolerated
in vivo (MTD .200mg/kg) makes MS-0022 a potential drug
candidate. In PANC-1 and SUIT-2 xenograft experiments, MS-
0022 treatment led to a partial response, where growth was
halted during the first days of treatment compared to the control.
Over time, however, both the treated and control xenograft
groups reverted to similar growth. In both SUIT-2 and PANC-1
xenografts, the growth delay in the MS-0022 treated group
resulted in a statistically relevant (P,0.05) average reduction in
tumor volume of subsequently 27% and 38%. Our in vivo results
lend support to the idea that the primary effect of Hh inhibition
in pancreatic cancer treatment is due to the inhibition of Hh
pathway activity in the stromal cells, although we also observe a
mild initial reduction of GLI1 levels in tumor cells. Both
pancreatic cancer cell lines, SUIT-2 and PANC-1, that were
xenografted as a part of this study, express high levels of Shh
mRNA (Table 4), and should be able to induce a Hh response in
stromal cells. It’s interesting to note that though both MS-0022
and GDC-0449, and to a certain degree cyclopamine, led to a
reduction of GLI1 mRNA in SUIT-2 cells in vitro, suggesting the
possibility to affect autocrine Hh signaling in this cancer cell line.
In an in vivo context, the effect of MS-0022 in vivo on SUIT-2 and
PANC-1 tumors was most likely due to an inhibition paracrine
Hh signaling since no statistically relevant reduction of either
hGLI1 or hPTCH could be measured in mRNA derived from the
tumor tissue. In contrast, mGli1 was reduced in the stroma of the
SUIT-2 tumors (P,0.05) after 7 days of treatment, but not at the
end of the treatment, while at the end of the treatment in PANC-
1 xenografts, there was a slight reduction of mGli1 (although with
a P.0.05). Reasons for the lack of a measurable reduction of
hGLI1 or hPTCH in the tumors, at the time points that were
taken, could be low levels of compound reaching the tumor, or
activation mutations that occurred within the tumors. Activation
mutations in SMO have been observed in a recent clinical trial
using CDG-0449 in a medulloblastoma patient [34,58]. Also, the
development of resistance against chemotherapeutic agents in
pancreatic cancer has been linked to both dense stromal matrix
and increased stromal barrier, which over time, may cause
resistance. Interestingly, Olive et al. found that treatment with
IPI-926 led to an increased vascularization in KPC tumors, but
similarly to our observations, the effect of this SMO inhibitor was
due to a developing resistance [41].
KPC mice develop pancreatic tumors that resemble human
pancreatic ductal adenocarcinoma due to a conditional expression
of endogenous mutant Kras and p53 alleles in pancreatic cells
[59,60]. Similarly, the SUIT-2 and PANC-1 cell lines are mutant
for p53 andKras [61–65]. Despite the differences in the twomodels,
with tumors forming in the mouse pancreas in the KPC model and
tumor cells injected under the skin in the in vivo xenograft model,
Table 4. Kinase activity in presence of 10 mM MS-0022 in a
kinaseprofiler diversity array.
kinase:
Activity
% kinase:
Activity
% kinase:
Activity
%
Abl(h) 96 EphB4(h) 99 NEK2(h) 127
ALK(h) 95 Fyn(h) 100 p70S6K(h) 94
AMPK(r) 98 GRK5(h) 119 PAK2(h) 93
ASK1(h) 91 GSK3b(h) 88 PDGFRb(h) 108
CaMKI(h) 106 IGF-1R(h) 105 Pim-1(h) 103
CDK1/cyclinB(h) 110 IKKa(h) 103 PKA(h) 100
CDK2/cyclinA(h) 98 IRAK4(h) 95 PKBa(h) 107
CDK7/cyclinH/
MAT1(h)
103 JAK2(h) 110 PKCa(h) 106
CDK9/cyclin
T1(h)
98 JNK3(h) 71 PKCh(h) 103
CHK1(h) 84 KDR(h) 103 PKG1a(h) 94
CK1c1(h) 93 LOK(h) 93 Plk3(h) 107
CK2a2(h) 109 Lyn(h) 103 PRAK(h) 71
cKit(h) 109 MAPK2(h) 101 ROCK-I(h) 103
c-RAF(h) 106 MAPKAP
-K2(h)
92 Rse(h) 107
cSRC(h) 83 MEK1(h) 73 Rsk1(h) 91
DRAK1(h) 97 MKK7b(h) 109 SAPK2a(h) 102
DYRK2(h) 97 MLK1(h) 103 SRPK1(h) 102
eEF-2K(h) 99 Mnk2(h) 90 TAK1(h) 98
EGFR(h) 84 MSK2(h) 92
EphA5(h) 112 MST1(h) 94
Millipore diversity panel - percent activity of tested kinases in the presence of
10 mM MS-0022.
doi:10.1371/journal.pone.0019904.t004
Table 5. Pharmacokinetics of MS-0022.
Cmax,
ng/ml
AUClast
ng*min/ml
AUCinf
ng*min/ml T1/2, min
Kel,
min-1
IV 934.3 87683.5 93897.6 59.27 0.0117
IP 377.7 25025.0 26237.8 54.83 0.0126
PO 912.0 64177.5 68526.0 59.10 0.0117
Pharmacokinetic profile of MS-0022 by IV, IP and PO administration in mice. The
table displays the maximum concentration (Cmax), total drug exposure
(AUClast) and (AUCinf), half-life (T1/2) and terminal slope (Kel).
doi:10.1371/journal.pone.0019904.t005
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both studies provide evidence that the pancreatic cancer may only
transiently be inhibited by a SMO antagonist, revealing that the
challenge of overcoming resistance is ever present.
Materials and Methods
Ethics statement
All animals were housed and treated under the approved
protocols in accordance with the National Institute of Health guide
for the care and use of laboratory animals and according to
regulations outlined in the USDA Animal Welfare Act (9 CFR Parts
1, 2 and 3) and the conditions specified in The Guide for Care and Use of
Laboratory Animals (National Academy Press, Washington, D.C.,
1996). Animal experiments performed in Norway were approved by
the Centre for Comparative Medicine at the National Hospital of
Norway according to the Regional Ethical Comity guidelines
(permit nr: 19/08-910) and at the Norwegian Institute of Public
Health (permit nr 2722), while animal experiments performed by
Chemdiv were approved by ChemDiv’s Institutional Animal Care
and Use Committee (Permit nr: 8/21.01.2008). All efforts were
made to minimize the number and suffering of animals.
Cells and culture conditions
PANC-1, PC-3, THLE-2, NIH3T3, Shh-Light 2 (Shh-L2) and
C3H10T1/2 cells were obtained from ATCC. SUIT-2 cells were
obtained from Cell Bank, RIKEN BioResource Center.
PTCH2/2 MEF [45] was a gift from P. A. Beachy and
SUFU2/2 MEF were a gift from R. Toftga˚rd (Karolinska
Institutet). FEMX was a gift from G. E. Melandsmo. All cell lines
were cultured at 37uC in a humidified atmosphere of 5% CO2 in
the medium formulations as instructed by the suppliers.
Alkaline phosphatase assay and screening protocol
C3H/10T1/2 cells were seeded 5*103 cells per well in a 96-well
format and allowed to attach for 3–5 hours, before adding serial
dilutions of compounds (from a DMSO stock). After 30 minutes
Figure 4. In vivo activity of MS-0022 in a SUIT-2 xenograft. A-F) Analysis of subcutaneous SUIT-2 tumors in mice treated with solvent control
or 50 mg/kg MS-0022 for 7 (n = 3) or 18 days (n = 8) by PO administration. A) Graph displaying average SUIT-2 tumor weight at end of treatment, with
SD. B) Tumor growth curve of SUIT-2 tumors in mice after 18 days of treatment, plotted as tumor volume (mm3) with standard error of the mean
(SEM). C) Average animal weight through the course of the treatment with SD (n = 8). D) and E) Graphs showing normalized (GUSB) fold expression of
mouse and human Gli1 and Ptch in treated tumors with SD. D) Shows expression in tumors harvested after 7 days (n = 3), while E) shows expression in
tumors harvested after 18 days (n = 8). F) Immunostaining of microvessles using anti-CD31 (endothelial cell marker) in cryosectioned tumor tissue
slides. Images depict CD31 staining in the tumor edge and in the centre of the tumors. * = P value ,0.05.
doi:10.1371/journal.pone.0019904.g004
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recombinant human SHH (C24II) (RnD systems (1845SH)) was
added (300 ng/mL). After 72 hours, the cells were lysed for 15
minutes using 20 mL of a 10 mM Ethanolamine Buffer (pH 8.0)
with 0.2% Triton-X100, supplemented 1:100 with Protease
Inhibitor Cocktail (EMD Bioscience). 7.5 mL of lysate was mixed
with 45 mL of CSPD Alkaline Phosphatase Substrate with
Emerald-II (Applied Biosystems) and incubated at room temper-
ature, in the dark, for 45 minutes. The plate was measured using a
Wallac VictorV reader (0.1 s Luminescence). Screening com-
pounds and MS-0022 were part of a Chemdiv chemical library.
Hh reporter assay
Shh-L2 cells were used as a Hh reporter cell line as described
previously [45]. Hh signaling was induced by Shh conditioned
medium, 200 nM SAG (AH-Diagnostics) and ActOXS (a
combination of 5 mM Hydroxycholesterol 20-alfa and 5 mM
Hydroxycholesterol 22S (Sigma-Aldrich)). For Shh conditioned
medium, Shh-PANC-1 cells were grown to confluence and
switched to fresh medium. Shh conditioned medium was harvested
after 48 hours, and was diluted to 50% in fresh DMEM before
use. The clonal Shh-PANC-1 cell line was generated by stably
transducing PANC-1 cells with virus containing medium from
HEK293T cells that were transfected using a Virapower Lentiviral
expression kit (Invitrogen). The vector was produced by removing
GFP from a pLenti 6.2-vector, and inserting the mouse Shh cDNA
sequence.
IC50 calculation
IC50 values were calculated using dose response curve data
where n= 3. The calculations were performed with an online
calculator using the formula: a exp (2bx) + c at the website;
http://www.changbioscience.com/stat/ec50.html
NMR spectroscopy of MS-0022
NMR spectra of MS-0022 (approx. 2 mg) were obtained from a
solution in 0.5 ml of DMSO-d6 ((CD3)2S(O), 99.9% D, Cam-
bridge Isotope Laboratories, Andover, MA) in a 5.0 mm tube
(WILMAD, WG-5 Economy). The spectra were acquired on an
Avance AV 600 MHz NMR spectrometer (Bruker BioSpin,
Rheinstetten, Germany) with a 5 mm CP-TCI (1H/13C, 15N-
2H) triple-resonance inverse cryo probe, equipped with a Z-
gradient coil. NMR assignments of MS-0022 were inferred from
examination of 1H- and 13C spectra, attached proton test (APT),
correlated spectroscopy (COSY45), total correlation spectroscopy
(TOCSY) pulsed field gradient heteronuclear single quantum
coherence (g-HSQC), pulsed field gradient heteronuclear multiple
bond correlation (g-HMBC) and pulsed field gradient hetero-
nuclear two-bond correlation (g-H2BC/g-HSQC-COSY). The
data were processed using the Bruker TOPSPIN software (version
1.3 or version 2.1 pl 2). Chemical shift values were referenced to
the residual solvent signals, i.e. CHD2S(O)CD3=2.49 ppm and
(CD3)2S(O) = 39.5 ppm, respectively. All NMR spectra were
acquired at 25uC.
BODIPY assay
BODIPY assay was performed to determine competition with
cyclopamine as described previously [21,66].
Real Time PCR
Cells were lysed for RNA extraction after 48 or 72 hours of
treatment. Total RNA from cultured cells or tumor tissue was
isolated using the GeneElute miniprep kit (Sigma-Aldritch)
following the manufacturer’s instructions. cDNA was synthesized
from the isolated mRNA using the Retroscript kit (Ambion), and
real-time PCR was carried out using the SYBR Green PCR
master mix (Stratagene) according to the manufacturer’s
instructions with an Mx3000P cycler (Stratagene). The relative
concentrations of cDNA present in each sample were calculated
by the MxPro software (Stratagene), normalized for GAPDH
(mRNA from cells) or GUS (mRNA from tumors). For real time
PCR primer sequences see Table 6. For the tumor tissue real time
PCR, previously described human and mouse specific primers
against GUSB, PTCH1 and GLI1were used [33].
Immunofluorescence
PTCH2/2 MEF were seeded on pre-coated glass slides (1
hour coating with 0.1% Gelatin (G1393) and 0.003% Collagen
(C8919) (Sigma-Aldrich) in PBS). 80% confluent cells were
switched from 10% to 0.5% FBS in medium and cells were
treated with DMSO or 5 mM MS-0022 for 24 hours in (n = 3)
before subsequent immunofluorescent staining: Slides were fixed
with 4% paraformaldehyde (Sigma-Aldrich), permeabilized for 10
min in 0.1% v/v Triton X-100 (Sigma-Aldrich) in PBS (PBT), and
blocked with 10% w/v BSA (Saveen Werner) in PBT for 1 hour.
Primary antibodies, mouse anti-acetylated tubulin (a-Tub) (Sigma-
Aldrich (T7451), 1:1000) goat anti-Smo (Santa Cruz Biotechnol-
ogy (sc-6367), 1:1000), and goat anti-GLI-1 (RnD systems
(AF3455), 1:500) were diluted in 0.5% w/v BSA in PBT and left
on the slides over night at 4uC. Secondary antibodies donkey anti-
goat IgG-Alexa 594 and donkey anti-mouse IgG-Alexa 488
(Invitrogen, both at 1:500) were added in 0.5% w/v BSA in PBT
for 1 hour. The slides were counterstained with DAPI (Roche,
Table 6. Primer sequences for quantitative real time PCR.
Primers: Primer sequence, 59 R 39 Tm,6C
hPTCH1 fwd CGA GCC CCC CTG TAC GAA GTG G 67.7
hPTCH1 rev GAC CCC CAG CAA GCC CAG AAA A 64.0
hGLI1 fwd GCG CAT CCC GAG CCC AGC 65.1
hGLI1 rev GCC CTC GGT GCA GCT GTT GGT C 67.7
hGLI2 fwd GCC TCC GAG AAG CAA GAA GCC AAA A 64.4
hGLI2 rev CCT GGT GTC GCA TGT CAA TCG GTA G 66.3
hGLI3 fwd CGG GAC GGT GTT TGC CAT GGA C 65.8
hGLI3 rev GGA GGA TGG AAG GCA GGG AAA AGA T 64.6
hSHH fwd GCC AGC GGA AGG TAT GAA GGG AAG 66.1
hSHH rev ACC GAG ATG GCC AAA GCG TTC AAC 64.4
hHIP fwd TGG GGA TGG CTC GCA ACG TCT C 65.8
hHIP rev TGG GAT GGA ATG CGA GGC TTA GC 64.2
hSUFU fwd CCC GAG GAT GAC GAG GAC AGC C 67.7
hSUFU rev CGC GTG CGA ATC AGC TCA TGG G 65.8
hSMO fwd CCA GGA GGA AGC GCA CGG CAA G 67.7
hSMO rev TCG CAC TGG CCT GAA CTG TTG AAC T 64.6
hGAPDH fwd GCC CCC TCT GCT GAT GCC CCC A 75.7
hGAPDH rev TGG GTG GCA GTG ATG GCA TGG 70.2
mGLI1 fwd AGC CAA CTT TAT GTC AGG GTC CCA GGG T 71.2
mGLI1 rev GAG CCC GCT TCT TTG TTA ATT TGA CTG 66.5
mGAPDH fwd TAT GTC GTG GAG TCT ACT GGT GTC TTC ACC 68.1
mGAPDH rev GAG TTG TCA TAT TTC TCG TGG TTC ACA CCC 66.8
Table of real time PCR primers; name, sequence and TmuC (h = human,
m=mouse).
doi:10.1371/journal.pone.0019904.t006
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1 mg/ml) in PBS. 3 random regions were imaged pr slide using a
confocal LSM510 microscope (Carl Zeiss MicroImaging). The
ratio of green Smo positive cilia versus the red aTub positive cilia
was quantified manually or processed and analyzed using ImageJ
to quantify the intensity of Smo and aTub for each cilium in the
images (http://rsb.info.nih.goc/ij/). Graphs display mean with
standard deviation error bars.
Frozen tumor tissue was cryosectioned (n= 8 pr group), and the
sections were fixed with 4% paraformaldehyde for 10 minutes
before permeabilization with 0.2% Triton-X in PBS for 10 minutes.
Sections were blocked for 30 minutes at room temperature with 3%
BSA in PBS and was subsequently incubated over night at 4uC with
rat anti-mouse CD31 (BD Biosciences (550274), 1:500) in 1% BSA
in PBS. The secondary antibody used was Alexa Fluor 488 goat-
anti-rat (Molecular Probes; 1/700 dilution) in 1% BSA in PBS for
1 hour at RT. Nuclei were counterstained with DAPI, in PBS for 10
minutes at RT. Images was acquired as above and electronic images
was further processed using ImageJ.
Transfection and luciferase assay
Vectors were obtained from the following: GliBS-Luc reporter
[67] (gift from H. Sasaki), pBluescript (pBS) (Stratagene), FL-HA-
GLI1 (Gli1) and Gli2-GFP (Gli2) (gifts from R. Toftga˚rd),
Super8XTOPFlash [68], and NFkB-luc (Panomics). 10 ng renilla
luciferase (pRL-TK) (Promega) was used as a transfection control.
HEK293 and NIH3T3 cells were seeded at 80,000 per well in 48-
well plates on day 1, and were co-transfected on day 2 using a total
of 0.4 mg plasmid per well mixed at 1:3 in FUGENE6 according to
manufacturer’s instructions. On day 3, control medium and
activating medium (50% L1 conditioned medium, 50% Shh
conditioned medium or medium containing 10 ng/mL recombi-
nant rcrTNF-a (R&D Systems)) +/2 10–20 mM MS-0022 were
added, using DMSO as a control (the NFkB pathway inhibitor
Bay11-7082 was used as a control in the NFkB assay). Samples
were analyzed on day 4 or 5 using the Dual Luciferase assay kit
according to manufacturer’s instructions. Graphs display relative
or fold reporter activity, and are calculated from a mean ratio of
firefly reporter luminescence/pRL-TK luminescence with stan-
dard deviation error bars (n = 3). The experiments have been
repeated with similar results.
In vitro antiproliferative assay
Cells were plated at a density of 3000 (THLE-2 and PC-3) and
1000 (PANC-1, SUIT-2 and FEMX) cells per well (on the basis of
their growth rate) in 200 ml of medium in a 96-well plate. Medium
was changed daily, and after four days, the assay was read using a
MTS kit (Promega) according to the instructions of the
manufacturer. Graphs display average of percent growth with
standard deviation (n= 8).
Passage growth assay
20,000 cells were seeded per well in 6 well plates (triplicates)
with DMSO or 5 mM MS-0022. Treatment medium was changed
on day 3–5, and after 5–7 days the cells were trypsinized, re-
suspended in medium and counted, before reseeding cells at
20,000/well for a subsequent passage. The average growth of MS-
0022 treated cells was calculated as a percentage of the growth of
the DMSO control at the end of each passage. Graphs display
average of percent growth with standard deviation bars (n = 3).
Soft agar colony formation assay
2000 PANC-1 or SUIT-2 cells were suspended in 1.5 mL
growth media containing 0.35% agar (Oxoid), over a 1.5 mL
base layer containing 0.5% agar in 6-well plates. The plates
were incubated for 14 days (SUIT-2) and 21 days (PANC-1)
and then stained for 1 h with 1 ml of 0.02% crystal violet
(Sigma-Aldrich), and colonies were counted according to sizes;
,0.2 mm (small), 0.2–1 mm (medium) and .1 mm (large).
Data represent average numbers with standard deviation bars
(n = 3). The experiments have been repeated with similar
result.
Pharmacokinetics, dose tolerance, animal tumor
establishment and treatment
For pharmacokinetic (PK) analysis, 5 mg/kg MS-0022 was given
by IV, PO and IP administration to 7–8 week old male C57BL mice
(mouse musculus), and blood was collected after 5, 15, 30, 60, 120, and
240 min, with n=3. Animals were sacrificed and blood samples
(,0.5 mL each) were collected from the abdominal aorta into
EDTA-containing tubes, centrifuged (2–8uC for ,10 minutes at
,10000 xg) and plasma harvested into single tubes for each animal
and frozen (,270uC). Blood samples were analyzed by ChemDiv’s
bioanalytical department. The maximum concentration (Cmax),
total drug exposure (the area under the curve to the last quantifiable
concentration (AUClast) and as the AUClast value extrapolated to
infinity (AUCinf), calculated as AUCinf=AUClast+C(t)last/Kel,
where C(t)last is the last measurable concentration), half-life (T1/2)
calculated as ln(2)/Kel and Kel calculated as the slope of the terminal
linear portion of the concentration/time curve. The WinNonlin
Professional 5.2 software (Pharsight Corp.) was used for the
calculation of the PK parameters.
For the analysis of uptake of MS-0022 in organs and tissue,
livers were dissected out from mice 120 min after PO adminis-
tration of MS-0022 and frozen (,270uC). The LC-MS method
used to detect MS-0022 was described previously [69], with the
main exception being that isocratic conditions were used (50%
0.1% FA (aq), 50% 0.1% FA (ACN), v/v), and that a UV detector
was placed between the LC and MS instrument.
MS-0022 tolerance was tested by daily injections of 200 mg/kg
MS-0022 for 5 days in 7–8 week old male C57BL mice. Animal
were observed daily for outward signs of toxicity (weight loss, fur
ruffling, hunched posture).
For PANC-1 xenografts, 4–6 week old CB17/SCID mice were
injected with 56106 PANC-1 (n= 6 per group) cells in 200 ml PBS
subcutaneously on day 1. IP treatment with 50 mg/kg MS-0022
began when median tumor size reached 25 mm2 (day 27). MS-
0022 was pulverized using a pestle, and was mixed into a stable
suspension in water containing 1% Tween 80 (Sigma-Aldrich).
Mice were treated with MS-0022 or solvent for a period of 30 days
after initiation in a 5 day injection 2 day pause scheme, and tumor
size was measured throughout using calipers (mm2). After 30 days
the mice were sacrificed and tumors dissected and weighed. The
PANC-1 xenograft endpoint was taken two days after the last
compound treatment.
For SUIT-2 xenografts, 4–6 week old CB17/SCID mice were
injected with 56106 SUIT-2 (n=11 per group) cells in 200 ml PBS
subcutaneously on day 1. IP treatment with 50 mg/kg MS-0022
began when median tumor size reached 35 mm2 (day 8). Mice were
treated daily with MS-0022 or solvent for a period of 18 days after
initiation, and tumor size was measured throughout using calipers
(mm2). After 8 days, three mice from each group were sacrificed and
tumors dissected, weighed and processed for analysis. The remaining
animals (n= 8) were sacrificed after 19 days of treatment, and tumors
harvested. Tumor volume (mm3) was calculated using the formula
a6b26,pi./6. End tumor measurement statistics were obtained
using two samples T-test in the Sigmaplot software.
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Liver transaminases
Blood was collected from the hepatic vein of freshly sacrificed
animals into heparinized capillary blood collection tubes
(Sarstedt), which were immediately centrifuged and the serum
was collected. AST and ALT were run on non-hemolyzed
samples using AST and ALT kits (Randox) following the
manufacturer’s instructions.
Supporting Information
Figure S1 Atom numbering of MS-0022. The atom
numbering of MS-0022 used in the 1H and 13C NMR analysis.
(See Table S1)
(TIF)
Table S1 NMR analysis of MS-0022. 1H and 13C NMR Data
for MS-0022 (DMSO-d6). For the atom numbering used see Figure
S1.
(DOC)
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